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ABSTRACT 
 
The purpose of this study was to develop a laboratory based Comprehensive Care, 
Management and Treatment of HIV and AIDS (CCMT) programme status reporting 
system using a methodological research study design. Quantitative data was collected 
using a request form and qualitative data was collected using structured 
questionnaires. For the study 1190 eligible CD4 samples were received, of which 1004 
(84%) had a valid CCMT programme status. Overall 32% of the CD4 samples had a 
pre-ART status (n=383) and 52% had an ART status (n=621). The remaining 16% of 
CD4 samples (n=186) did not have a valid CCMT programme status. A pre-ART 
register was generated and assessed using a structured questionnaire. Based on the 
study findings a recommendation has been made to adopt the two-tick design for all 
NHLS request forms where programmatic data is collected. Additionally the CCMT 
programme status reporting system is recommended for rollout to other health 
districts.  
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CHAPTER 1: ORIENTATION TO THE STUDY 
 
Human Immunodeficiency Virus (HIV) infection and Acquired Immune Deficiency 
Syndrome (AIDS) are one of the main public health challenges facing South Africa. It 
is estimated that of the 33.3 million people living with HIV worldwide in 2009, 67% are 
from Sub-Saharan Africa (22.5 million), of which 25% (5.3 million or 11% of the SA 
population) reside in South Africa (Rehle, Hallett, Shisana, Pillay-van Wyk, Zuma, 
Carrara and Jooste 2010:1).  
 
In 2003 the South African government initiated the Comprehensive Care, 
Management and Treatment of HIV and AIDS (CCMT) programme. The National 
Department of Health (NDOH) outlined its plans to extend the HIV & AIDS and STI 
Strategic Plan for South Africa 2007-2011 (NSP) (NDOH 2009:10) in 2007. The 
primary aim of the NSP was to reduce HIV incidence by 50% and to expand access 
to treatment, care and support to 80% of people who need it by 2011 and beyond 
(Rehle et al 2010:1).  
 
In April 2010, to strengthen its response to the HIV epidemic, the NDOH launched an 
HIV Counselling and Testing (HCT) Campaign that aimed to test 15 million individuals 
by July 2011 (SANAC 2011). The objectives of the HCT campaign are to mobilise the 
South African population to know their HIV status, provide key prevention messages 
to promote healthy lifestyle choices irrespective of HIV status, increase the incidence 
of health seeking behaviour, and to increase access to treatment, care and support 
(Red Ribbon 2011). By December 2012, the DHIS reported that 2 million people were 
enrolled on ART in South Africa (Magoro 2013).  
 
Indicators were developed to manage and generate reports on the roll out of ART in 
South Africa for the monitoring and evaluation (M&E) of the CCMT programme. These 
included the proportion of patients starting ART with a CD4 below 50 and the number 
of CD4 tests performed pre-ART as a percentage of HIV infected patients (NDOH 
2009:113) The introduction of the Monitoring & Evaluation Framework for the NSP 
(NDOH 2009:105) further strengthened HIV M&E efforts. Specific M&E indicators have 
subsequently been routinely collected using a combination of a paper based (at facility 
level) and aggregate reporting (at health district level) using the District Health 
Information System (DHIS). Despite the presence of electronic systems existing at 
facility level, data is not integrated into a national M&E reporting system. Sites using 
paper based data systems are even more difficult to manage as data completion is 
erratic with low data completion rates despite efforts to provide training (Garrib, 
Stoops, McKenzie, Dlamini, Govender, Rohde and Herbst 2008:550). There is no 
recorded formal NDOH database with ART enrolment data or patient follow-up 
records. Only limited data sources are available to correlate the data collected by the 
paper-based pre-ART registers e.g. the ART enrolment numbers related to the supply 
of ART medicines for examples.  
 
According to Rosen and Fox (2011:7), in Sub-Saharan Africa, a median of 55% of 
patients that had a positive HIV test reached the study endpoint, which consisted of a 
repeat CD4 count, ART initiation, 12 month follow-up visit or data censoring. This study 
emphasized the importance of reporting tools to assist facility managers to identify 
potential pre-ART loss to follow-up. The high pre-ART loss to follow-up during CD4 
screening poses a major programmatic challenge that could be addressed with 
improved pre-ART M&E reporting and programmatic interventions.  
 
The National Health Laboratory Service (NHLS) developed a national database of 
laboratory results which has indirectly provided valuable information about the 
numbers of patients accessing the CCMT programme in South Africa. This is possible 
because each NHLS CD4 laboratory has a Laboratory Information Management 
System (LIMS) enabling capture of patient demographics, details of referring health 
facility and CD4 results. The LIMS at each laboratory replicates this information daily 
to the Corporate Data Warehouse (CDW) which is based at the NHLS corporate head 
office. This stored data currently provides the NDOH with specimen level laboratory 
data for the CCMT programme. However, CD4 laboratory records do not differentiate 
between CD4 testing performed at the time of HIV Voluntary counselling and testing 
(HCT) /pre-ART screening versus those same CD4 tests that are used to monitor 
patients already enrolled on ART. The ability to track individual patients, who are 
accessing HIV care for the first time versus those who are subsequently followed on 
wellness programmes or enrolled onto ART, would provide a valuable tool to review 
numbers of new patients accessing the public health care system, a means to provide 
some information about loss to follow-up and give an indirect indication about 
programmatic performance. 
 
Unfortunately the absence of unique patient identifiers (a unique number or code 
which would identify a single patient irrespective of where the patient presented 
him/herself for counselling or treatment) in the existing NDOH system makes 
identification of patient programme status and longitudinal review difficult. 
 
Therefore, in the absence of such unique patient identifiers, this research study aims 
to establish a system whereby patients CD4 results can be identified as first or 
subsequent-visit CD4 counts linked to patient samples. Information including clinical 
data about the patients status in the CCMT programme on the laboratory request form 
would be invaluable e.g. HCT, first ever CD4 count, not yet on ARV’s and on ART, will 
be collected on the LIMS, with the CD4 count, and accessible for data review within 
the CDW.  
 
The aim of this report was to develop a system to characterise CD4 as described 
above. To achieve the objectives of this research study, the CCMT programme status 
information was incorporated into the laboratory request form linked to request for CD4 
enumeration, with training provided to both health care workers (on how to complete 
the request forms) and laboratory data capturers (on the capture of the programme 
status information on the LIMS). Specific capture fields were set up on the LIMS to 
facilitate easy data capture of the CCMT programme status. Throughout the project, 
regular follow-up visits and feedback sessions with the health facilities and laboratories 
were conducted to ensure data quality. Data was extracted from the CDW and 
analysed using Excel and Stata software. To protect the identity of patients, patient 
identifiers were not included for the study. 
 
1.1 Research problem 
 
The absence of a national electronic HIV M&E system to monitor CD4 patient data 
characterised according to their pre-ART and ART status in the CCMT Programme 
prevents the NDOH from monitoring the impact of their HCT campaigns. A system is 
needed which will facilitate monitoring number of patients accessing the system for 
the first time versus those enrolling onto ART or during follow-up. Meaningful analysis 
of this data will facilitate the analysis of CD4 data for both patients accessing the HCT 
campaign and those already enrolled in ART care (wellness programs or treatment). 
 
1.1.1 The source of the research problem 
 
No national M&E data system currently exists to monitor CD4 data for patients in the 
pre-ART and ART components of the CCMT Programme. While CD4 laboratory data 
is reported, the ability to report the data by CCMT Programme Status is not available. 
 
1.2 Background to the research problem 
 
The initiatives of the CCMT Programme have led to increased access to ART in South 
Africa. The rapid scale up of ART provision in South Africa resulted in two million HIV 
infected individuals being placed on ART by December 2012 (Magoro 2013). Despite 
the large scale HIV testing campaign  initiated in 2010 to accelerate HIV diagnosis, as 
well as raising the CD4 treatment eligibility to 350 cells/µl, patients are still presenting 
at a very late stage of their illness for ART initiation (Rosen and Fox 2011:2). A local 
study utilising HIV treatment and care programme data, reported  a median CD4 cell 
count 263 cells/µl at first presentation and 145 cells/µl prior to ART initiation (Lessells, 
Mutevedzi, Cooke, and Newell 2011:79). Another local study, conducted in the rural 
uMkhanyakude district, longitudinal population-based HIV and health surveillance was 
conducted to assess the variability of CD4 counts in the general population. This study 
reported that the median CD4 count was 775 cells/µl for HIV-uninfected individuals vs. 
374 cells/µl for HIV-infected individuals (Malaza, Mossong, Barnighausen, Viljoen and 
Newell 2013:4)  
 
Failure to link patients from HIV testing to HIV care (CD4 test, ART, etc.) is now 
recognised as the key factors leading to late presentation for ART enrolment (Rosen 
and Fox 2011:2).  
 
The study by Clouse, Pettifor, Maskew, Bassett, Van Rie, Behets, Gay, Sanne and 
Fox (2013:39) reviewed retrospective clinical records at the Witkoppen health and 
welfare centre to compare the retention of patients at three stages of pre-ART care 
and two stages of ART care. The aim of their study was to identify when the greatest 
attrition occurred between HIV diagnosis and treatment on ART (Clouse et al 
2013:39).  Three stages of pre-ART care were defined. (i) The pre-ART stage one 
category was for patients that had completed CD4 staging within three months of HIV 
diagnosis (Clouse et al 2013:41). (ii) The next stage was pre-ART stage two category 
that included all patients that were not eligible for ART (based on their CD4 result) who 
completed their CD4 test within 12 months of the first CD4 staging date (Clouse et al 
2013:41). (iii) The pre-ART stage three category was for patients that had been 
initiated on ART within three months of an eligible CD4 count. The patient retention 
rates for the three pre-ART categories were 69.8%, 57.4% and 36.9% respectively 
(Clouse et al 2013:41). 
 
This study demonstrated the poor level of pre-ART retention in care. Retaining patents 
in HIV care from the time of testing HIV positive through to lifelong ART is critical for 
getting patients onto treatment promptly and preventing the morbidity and mortality 
associated with disease progression (Clouse et al 2013:41).  
 
In 2008, the World Health Organisation (WHO) proposed the deployment of a pre-
ART/ HCT register, in addition to ART register, to improve the linking of patients in HIV 
care (WHO 2006:58). Paper-based pre-ART/HCT and ART registers were introduced 
in South Africa in 2010 and data is reported at the health district level on the 
Department of Health Information System (DHIS). Data entry is however labour 
intensive on this existing system and is not integrated into a national database. Locally, 
results from a study at the Themba Lethu Clinic (TLC) in Johannesburg, reported that 
only 51.3% of HIV diagnosed patients eligible for ART had completed CD4 testing 
within 12 weeks of their initial HIV test (Larson, Brennan, McNamara, Long, Rosen, 
Sanne and Fox 2010:677). 
 
A recent study by Mate, Bennett, Mphatswe, Barker and Rollins (2009:3) in the 
KwaZulu-Natal province found that the DHIS data was incomplete in approximately 
50% cases and that critical PMTCT data elements being studied, including CD4 testing 
of HIV positive pregnant women and HIV PCR test of babies born to HIV+ women at 
6 weeks or later, were missing from the clinic registers in 5 to 41% of cases (Mate et 
al 2009:3).   
 
The existing CCMT request form of the NHLS (Form 3 Page 95) was deployed in the 
Gauteng, North West, Limpopo, Mpumalanga and Free State provinces in 2006. This 
request form was designed to include a programme status data collection tool, 
however the implementation was mainly focussed on utilising this request form for 
billing purposes (conditional grant). The Western Cape and Eastern Cape provinces 
were using alternative versions of the current NHLS CCMT request form (Form 3 Page 
95). In 2012, the NDOH and NHLS agreed to develop a national CCMT request form 
(Form 4 page 96) that would be used throughout the public health care system and 
would be designed to collect the CCMT programme status data in a standardised 
manner. Additionally, the LIMS used within the NHLS would utilise specially designed 
test methods to collect this programme status data using standardised LIMS codes. 
 
The use of the new CCMT request form (Form 4 page 96) and the LIMS will provide a 
more robust and reliable M&E system to identify whether CD4 testing is being 
performed for pre-ART screening or ART monitoring. This data is required to track the 
linkage of care from HCT to CD4 testing and finally to ART provision. This information 
will provide the NDOH with valuable information on the number of patients being tested 
(CD4) following HCT versus those who are receiving ART. 
 
The new CCMT request form (Form 4 page 96) was developed by the NHLS, in 
consultation with the NDOH, as part of a process to propose and design national 
laboratory request forms for use in the public health sector. The primary health care 
(PHC), hospital and national programme forms were developed. This study evaluated 
the new CCMT request form (Form 4 page 96) (national programme request form). 
 
 
 
 
 
1.3 Aims of the study 
 
1.3.1 Research purpose 
 
The purpose of this study is to develop laboratory based CCMT Programme Status 
reporting system through the use of specific modifications to the current CCMT request 
form (Form 4 page 96) and thereafter, to the NHLS LIMS to enable appropriate capture 
of the CCMT programme status for CD4 samples. The information will be used to 
generate supplement exiting M&E reports to assist programme management at the 
health facilities. These reports will help the health personnel at the facilities to 
differentiate between CD4 counts taken before the patient commenced treatment (i.e. 
pre-ART screening) and those CD4 counts taken later during patient follow-up that are 
used to assess response to treatment (i.e. ART monitoring. The data generated by the 
study will help the facility manager to plan for and anticipate new patients who are 
likely to be eligible for enrolment onto ART programmes based on the CD4 median of 
the pre ART group. Once implemented across all health districts this data could be 
used at a national level to make relevant programmatic decisions about the extent of 
patients eligible for care and at which sites these patients are presenting. 
 
1.3.2 Research objectives 
 
The study will develop the laboratory based CCMT Programme Status reporting 
system to answer the following objectives in a limited cohort:- 
 Establish the impact of use of the tick box system for the capture of the CCMT 
programme status. 
 Establish the median CD4 for ‘pre-ART’ and ‘ART CCMT’ programme status 
groups as an indirect indicator of overall patient programmatic immune status. 
 Establish the percentage of patients with pre-ART and ART programme status 
categories as a percentage of total CD4 samples received, to define eligibility for 
treatment. 
 Establish the proportion of patients eligible to start ART with a CD4 count below 
50.  
 Establish the number of patients that were eligible for ART, but not yet enrolled 
onto treatment programmes. 
 Establish the usefulness of the laboratory pre-ART register (assessed with a 
questionnaire). 
The study will also provide insight on the provision and capture of the CCMT 
Programme Status information. This insight will enable the researcher to develop 
practical guidelines for the implementation of the CCMT Programme Status reporting 
system to other health districts. 
 
1.4 Significance of the study 
 
The outcomes of this study will improve how the CCMT programme is managed at the 
district and facility level by providing information on whether patients are accessing 
the system for first or subsequent visits during ART. Potentially, it can assist facility 
managers to improve the health facility utilisation and reduce loss to follow-up. Overall 
the ultimate outcome of the study will be improved patient care. 
 
1.5 Definition of terms 
 
Antiretroviral Therapy (ART): Standard antiretroviral therapy (ART) consists of the 
combination of at least three antiretroviral drugs to maximally suppress the HIV virus 
and stop the progression of HIV disease. Patients that are enrolled in the CCMT 
programme are receiving Antiretroviral Therapy. 
 
Pre-Antiretroviral Therapy (Pre-ART): Patients that are diagnosed as HIV positive 
but not yet eligible for ART enrolment. The eligibility for ART enrolment is determined 
either through a clinical assessment or by a CD4 count below 350. 
 
Register: A document used at the health facility to capture all the information about a 
patient’s pre-ART care, for example. The Pre-ART register documents the basic 
demographic and clinical information about patients with HIV attending a health facility. 
The register will be kept in the health facility and allows the health care worker to 
monitor the progression in the CD4 count for each patient, and the demand for ART 
to be anticipated. 
 
Programme Status: is the status of a patient in the continuum of HIV care. The 
programme status aspects relate to the status of the patient once diagnosed with HIV. 
The programme status categories include HIV diagnosis (at an HCT or PMCTC 
service point), CD4 staging for ART enrolment and currently on ART treatment. 
 
HIV counselling and testing (HCT) (also known as VCT): describes voluntary 
counselling and testing. An individual can on a voluntary basis decide to take an HIV 
test that is performed confidentially. The individual must receive counselling before 
and after the HIV test. The South African government launched an expanding access 
to HIV counselling and testing that is seen as a critical gateway to HIV prevention as 
well as providing appropriate treatment and care for people who are already infected. 
This massive testing campaign was initiated in April 2010 and aimed to test a total of 
15 million people throughout South Africa by the end of June 2011.  
 
Laboratory Information Management System (LIMS): A laboratory information 
management system (LIMS) is a series of computer programs that processes, stores 
and manages laboratory data at all stages of the testing procedure. This kind of 
information system is used in laboratories for the management of the data related to 
samples received, instruments used to test these samples and other laboratory 
functions such as recording quality control performed as well as management 
reporting and storing of patient results. 
 
National Health Laboratory Service (NHLS): The NHLS is the largest diagnostic 
pathology service in South Africa with the responsibility of supporting the National and 
Provincial Department of Health in the delivery of healthcare. The NHLS provides 
laboratory and related public health services to over 80% of the South African 
population through a national network of 265 laboratories. 
 
National Department of Health (NDOH): is a national department in the South 
African government with a mission to improve health status of the population through 
the prevention of illnesses and the promotion of healthy lifestyles. The NDOH aims to 
consistently improve the healthcare delivery system by focusing on access, equity, 
efficiency, quality and sustainability through the delivery of health care services at 
public health care facilities across the country.  
 
Health District: The nine provinces of South Africa are divided into 53 health districts. 
The health districts focus on issues related to the general health of the population at 
district and provincial level. 
 
District Health System (DHS): is the organisation of health care according to 
geographic sub-divisions of a country (health districts), which are managed through a 
decentralised management structure.  
 
CD4 Count: Along with other tests, the CD4 count indicates the status of the patient’s 
immune system, the stage of HIV/AIDS disease, acts as a guide to determine eligibility 
for treatment and predicts how the disease may progress. The CD4 Count is a 
laboratory test performed on a sample of blood drawn by venepuncture, using the 
PanLeucogate (PLG) CD4 test method as standardized test (Glencross, Scott, Jani, 
Barnett and Janossy 2002:73) 
 
1.6 Conceptual framework 
 
The conceptual framework was derived from the published literature relating to the 
M&E systems required for the CCMT Programme. Various key concepts have been 
identified as elements that feature as central to the CCMT M&E system. A conceptual 
map was used to illustrate relationships between the different concepts (refer to 
Annexure K Page 157). 
 
1.6.1 Key components of a CCMT Monitoring and Evaluation (M&E) System 
 
An effective well-functioning CCMT M&E system relies on various inputs to determine 
what data will be generated as outputs. The inputs into the system guide what will be 
measured as well as how they will be reported. An example of such input is the tiered 
ART M&E implementation plan that defined standardising ART monitoring at health 
facilities as well as district and provincial management, that would track and respond 
to the expansion of ART services (NDOH 2011e:7). 
 
The CCMT M&E systems depend on clear government policies to direct health care 
interventions. For example the District Health Management Information Policy guides 
the long term M&E goals of the NDOH to develop a National Health Management 
Information System (NHMIS) (NDOH 2012a:10). The NDOH policies and guidelines 
determine the M&E data to be collected as well as the indicators to be reported. The 
NDOH, via the NIDS process, develops the health indicators and associated data 
elements that must be reported (NDOH 2012a:19). The health care workers are the 
enablers that implement the policies and guidelines into health care practices and 
facilitate the collection of data using the M&E data systems. 
 
The CCMT programme regularly updates its clinical guidelines, which guide how 
health care provision is offered throughout the country by health care workers, i.e. the 
new antiretroviral treatment guidelines that were released in 2010  (NDOH 2010:1). 
This change introduced access to ART for all HIV-infected infants, pregnant women 
and people with TB and HIV at CD4 less or equal to 350 cells/µl (NDOH 2010:8). This 
guideline changes required the M&E system to modify indicators to reflect the changes 
in the ART enrolment criteria. Therefore guidelines facilitate the implementation of 
government policies into routine health care provision, whereby trained health care 
workers execute the new plans (such as ART provision). The M&E units also release 
new data tools, such as the pre-ART register, to update data reporting systems and 
cater for the new national indicator dataset (NIDS) reporting requirements  (NDOH 
2012a:19). 
 
The M&E systems require competent and trained health care workers that are able to 
utilise the data tools such as the tiered ART system M&E framework, DHIS and pre-
ART register to deliver the required data at the facility level. For the tiered ART M&E 
implementation plan the district implementation teams are required to perform a facility 
assessment prior to implementation. This assessment will establish whether there has 
been a delegation of responsibility from the facility manager to existing data staff to 
support the data capturing. Additionally the plan requires that facility manager 
understands the process that is underway, the importance of folder flow, clinical 
stationery and its management, and the data that is generated from the monitoring 
tool (NDOH 2011e:11).  Extensive training of health care workers is discussed in the 
tiered ART M&E implementation plan including “train-the-trainer” sessions, district 
implementation training, training for health care workers on the new standardised 
based systems, as well as  training on how to use the information for both programme 
management and reporting (NDOH 2011e:21-27). 
 
A data system comprising of paper based and electronic data collection systems form 
the next key component of a CCMT M&E system. The most common data system 
used is nurse or clinician based notes following a patient encounter.  These clinical 
notes are captured by the health care worker during patient visits. The next level of 
data systems is the paper based register that has been designed for a specific 
purpose, e.g. pre-ART or malaria register. The pre-ART registers identifies all patients 
that had a HIV positive test result but are not yet eligible for ART enrolment. The next 
step is the move to an electronic system to collect patient data. These electronic 
systems are customised to meet a specific need. In a hospital setting, the Hospital 
Information System (HIS) would be employed, and in special disciplines within a 
hospital, data systems such as the Laboratory Information System (LIS) and Radiology 
Information System (RIS) may be used (Shortliffe and Cimino 2006:453). At a health 
facility level various electronic medical record (EMR) systems may be used (Shortliffe 
and Cimino 2006:503). The tiered ART M&E system is an example of an EMR. In 
many countries data from multiple electronic systems are integrated into an electronic 
health record (EHR) that integrates all patient data from multiple systems into a single 
system (Shortliffe and Cimino 2006:453). 
 
The data collected from paper based and/or electronic systems is often aggregated 
and captured using a national district health information system (DHIS). All of the data 
systems described allow for the collection of data to facilitate M&E. The DHIS was 
introduced in the South African public health sector in 1994 as the national standard 
system for the capture, storage, analysis, and reporting of routine health data (NDOH 
2012a:11). The DHIS provides a large proportion of the information used for planning, 
budgeting, health service management, M&E at all levels of the South African health 
care system. This aggregated data is used for indicator and related target reporting 
(NDOH 2012a:11). 
 
Figure 1.1: Conceptual framework for CCMT M&E Systems 
 
All of the components of the conceptual framework for the CCMT M&E system 
contribute to determining the data to be collected. The conceptual framework 
described above represents the ideal CCMT M&E systems. The current South African 
CCMT M&E systems do not meet these ideals as current electronic patient record 
systems are not universally used by the majority of health facilities as they are either 
using paper based registers or non-networked current electronic patient record 
systems. Additionally data collected by the existing NHLS laboratory information 
system is not integrated into the CCMT M&E system. For the ideal CCMT M&E 
systems data needs to be available to flow from the M&E systems to the District Health 
Information System, and between the different M&E data systems. 
 
1.7 Scope of the study 
 
The study was undertaken in one health district in the Gauteng province. Three 
hospitals in the Ekurhuleni health district were selected based on CD4 test volumes. 
The study required health care workers to complete the new CCMT request form 
(Form 4 page 96) and submit them to their local laboratories. At each laboratory the 
CCMT programme status was captured in the Laboratory Information System (LIMS) 
by data capturers.  
 
This study was designed to develop an electronic M&E system to report the CCMT 
programme status for CD4 results using the new CCMT request form (Form 4 page 
96). The CD4 results and CCMT programme status data was captured in the LIMS 
and then replicated to the CDW, from which data was extracted.  
 
The candidate led the research project, planned and coordinated all the study activities 
such as designing the data collection instruments, providing training for health care 
workers and laboratory staff as well as conducting follow-up visits. The dissertation 
will provide quantitative data collected using the new CCMT request form (Form 4 
page 96).  
 
1.8 Structure of the dissertation 
 
The dissertation is structured into chapters, the first being the orientation to the study 
(this chapter).  
 
The literature review chapter (2) identifies and critically evaluates the available 
information in the form of journal articles, books and National Department of Health 
policies.  
 
In the research design and methods chapter (Chapter 3), the research population and 
sample as well as the sampling approach used is described. 
 
The next chapter (Chapter 4) describes the analysis, presentation and description of 
research findings. This chapter outlines the research findings of the study and data is 
presented by means of tables, graphs and histograms. 
 
The final chapter (Chapter 5) is the conclusions and recommendations chapter that 
reports the findings of the research in relation to the research problem and problem 
statement. 
 
CHAPTER 2: LITERATURE REVIEW 
 
2.1 Introduction 
 
This chapter will discuss the related literature reviewed for this study which outline key 
the concepts. 
 
2.2 Purpose of the literature review 
 
The purpose of the literature review is to identify and critically evaluate the available 
information available at the time of writing this dissertation, in the form of journal 
articles, books and National Department of Health (NDOH) policies.  
 
2.3 Scope of the literature review 
 
The NDOH policies, reports and documents were searched to identify current and new 
HCT and ART M&E systems.  
 
Additionally a literature search was requested from the UNISA library to identify 
literature sources for the following keywords; “HIV Programme Status”, “Pre-ART 
Register”, “First ever CD4”, HIV Counselling and Testing”, “Baseline CD4”, “CD4 
Median” and “Request form”, “HIV M&E”. The Google scholar search engine was also 
used to search for literature using the keyword “laboratory register”. Additionally the 
Google scholar search engine was used to search for literature articles for the 
keywords above. 
 
The literature review is presented according to the following headings:- 
 development of a tiered ART M&E framework in South Africa 
 the pre-ART register 
 development of a National Health Information Network (NHIN) 
 current challenges with collecting ART data using paper based systems 
 current challenges with collecting ART data using electronic medical record 
systems 
 the laboratory register 
 development of a national laboratory based data repository 
 
2.4 Development of a tiered ART M&E framework in South Africa 
 
The NDOH set a goal in 2008 to integrate health record systems in the country by 
bringing together all the different health information systems facilitating access to 
health records within a province and across provinces (NDOH 2008:7).  
 
In a review conducted by the NDOH in October 2010, over 40 different ART patient 
management systems and various non-standard non-networked M&E systems were 
identified in the public health sector (Pillay, White and McCormick 2012:77).  This 
identified the lack of standardisation of data collection and reporting for ART provision 
in South Africa. The study further identified the use of multiple versions of clinical 
stationery. In May 2010, the NDOH adopted standardised registers and clinical 
stationery to assist with capturing and tracking ART patient information 
at health facilities (Pillay et al 2012:77).  
 
On the 1st of March 2011, the NDOH HCT Campaign and ART Expansion update to 
provinces and districts announced that a three tiered ART monitoring strategy would 
be introduced that would comprise of a paper based system (known as Tier 1), a non-
networked electronic register (known as Tier 2) and finally a fully networked electronic 
patient register (known as Tier 3) (NDOH 2011c:3-6). 
 
According to the NDOH, this strategy would enable health facilities to manage their 
ART patient data with the system that best suits their context (2011c:2-4). Tier 1 
consists of a non-networked, non-electronic paper based system that will utilise 
standardized clinical stationery and the standardized paper-based registers to collect 
information for the NDOH CCMT monthly and quarterly reports (NDOH 2011e:16). 
The next tier, Tier 2, is a non-networked electronic stand-alone system that uses an 
electronic register identical to the paper-based registers used in Tier one (NDOH 
2011e:17).The final tier, Tier 3, is a fully networked electronic patient management 
system that has some additional functionality such as the ability to import electronic 
patient information. This could be considered to be a module of the longer term EHR 
strategy (NDOH 2011e:15). 
 
The NDOH identified that to implement this strategy they would have needed to 
consider the system requirements for space, infrastructure, networks, staffing, registry 
management and standardised clinical stationery (NDOH 2011e:15).  In April 2011, 
the NDOH released the tier T1 and tier T2 ART M&E implementation plan (NDOH 
2011e:1). This plan described how provincial and health district implementation teams 
would deliver a tiered ART monitoring strategy. It outlines the specific set criteria that 
will assist in selecting the appropriate monitoring systems based on number of patients 
on ART at a health facility, implementation of standardised clinical stationery, folder 
management and staffing (NDOH 2011e:15). 
 
The NDOH tiered ART M&E implementation plan states that standardised clinical 
records are the most basic of clinical tools and they are the international standard of 
care in chronic disease management. Standardised records support the clinical 
management of patients and provide the source data to data capturers for the routine 
monitoring of patient enrolment and clinical outcomes (NDOH 2011e:14). The 
minimum set of standardized stationery that will be used for the tiered ART M&E 
system includes the patient summary, visit summary, patient card and laboratory 
results forms (NDOH 2011:14). 
 
The DHIS in South Africa consists broadly of two parts, the first being data collection 
at the health facility level and followed by the analysis of the data (Garrib et al 
2008:550).  The DHIS aggregate data is collated at the sub-district or district level from 
reporting health facilities and entered using the DHIS software (Garrib et al 2008:550). 
The aggregate DHIS data was analysed, and reported at the district, provincial and 
national levels (Garrib et al 2008:550). In this way the three tiers of the tiered ART 
M&E framework generates data into the national DHIS data set used by the NDOH for 
M&E of health services (NDOH 2011e:23). According to the tier T1 and tier T2 ART 
M&E implementation plan, the DHIS is the primary repository for reporting routine 
health services data (NDOH 2011e:23). 
The NSP 2012-2016 has set a target to complete the rollout of the tiered ART M&E 
system for ART 2013/14 (NDOH 2011d: 50). Furthermore the NSP calls for a clear 
M&E framework that would require a single national unique patient identifier that would 
facilitate improved M&E, seamless transfer of patient information, improved referral 
and tracking, decreased duplication of laboratory and radiological investigations, and 
harmonisation of information systems (NDOH 2011d:44).  
 
By March 2013 the NDOH had 10 health facilities fully implemented at Tier 3 which is 
the fully networked electronic patient register (White 2013). In South Africa, 1361 
health facilities offering ART are eligible to implement Tier 2 (non-networked electronic 
register) as they have 500-2000 patients currently enrolled on ART (White 2013). By 
March 2013, a total of 887 (52.9%) eligible health facilities were implementing Tier 2 
(White 2013). Additionally there were 654 health facilities not eligible to implement Tier 
3, that were allowed to start implementing Tier 2 (White 2013). All the health facilities 
implementing Tier 2 were classified into seven stages of implementation with “Tier 
Phase 0” indicating that these sites were preparing for implementation. To achieve the 
final phase of implementation, “Tier Phase 6”, health facilities should have completed 
data signoff to be considered as a live site (White 2013). By March 2013 of the 1361 
Tier 2 eligible sites, 43.5% (n=593) had reached the final Tier Phase 6 level of 
implementation (White 2013). All the health facilities that have reached Tier Phase 6 
would be able to utilise the application for cohort reporting whereby patients can be 
followed up over time (White 2013).  
 
A major challenge for the tiered ART M&E strategy is that most health facilities in 
South Africa have only deployed either Tier 1 or Tier 2, with only 10 health facilities 
using Tier 3 (White 2013). A local study by Sorensen et al (2008:39-40) highlighted 
that with the exception of the major Health Information System (HIS) or Electronic 
Health Record (EHR) systems in South Africa, none of the ICT systems were ready to 
be deployed in the country as a whole. They (Sorenson et al 2008:40) concluded that 
paper based and ICT systems would coexist in South Africa for some time to come. 
Until the majority of health facilities offering ART have transitioned to Tier 3, it would 
be difficult to make the progression to a national EHR. 
 
The NDOH tiered ART M&E framework, once fully implemented would achieve the 
standardisation of ART records for the routine monitoring of patient enrolment and 
clinical outcomes in South Africa. The tiered approach also allows health facilities to 
develop their exposure to M&E systems by transitioning from Tier 1 to Tier 3 in a 
phased approach.  
 
2.5 Pre-ART Register 
 
For patients not yet eligible for ART (pre-ART), the tiered ART M&E framework does 
not apply. Instead these patients will be monitored using facility based pre-ART paper 
registers. Some of the paper based monitoring systems used to capture health 
information for patients include the pre ART register, ANC register and TB card and 
registers (NDOH 2011b:24). The NDOH Clinical Mentorship Manual for Integrated 
Services was developed in 2011 (NDOH 2011b:1). This document lists that the HIV 
care/ART card, pre ART and ART registers are used for patient monitoring in HIV care 
(NDOH 2011b:25). The ART card will be replaced by the standardized stationery 
utilised by the tiered ART M&E system, however the pre-ART register will still be 
utilised by health facilities (NDOH 2011e:14).  
 
The Pre-ART register should therefore be used by health facilities to record all patients 
who are enrolled in HIV care and counted as enrolled in HIV care (WHO 2006:58). 
Data will be recorded in the pre-ART register until the patient starts ART (WHO 
2006:58). The ART register is only used when patients start ART (WHO 2006:58). The 
data from the pre-ART register will be collated and reported using the DHIS. 
 
Patients may attend a health facility for more than one condition that requires tracking 
using several patient cards. Consequently linkages need to exist between information 
reported for HIV care and cards or records for family planning, TB treatment, antenatal 
care and PMTCT. This is achieved through the use of transfer forms to facilitate 
referrals between services (WHO 2006:58). The challenge with the pre-ART register 
is that it does not form part of an electronic M&E system as the data is collated from 
paper registers and reporting on the DHIS. 
 
2.6 Development of a National Health Information Network (NHIN) 
 
Early in 2012 the NDOH released an ambitious plan for the creation of National Health 
Management Information System (NHMIS) which builds on the tiered ART M&E 
strategy (NDOH 2012a:10). The NHMIS plans to integrate data from the source 
systems such as the tiered ART system and DHIS (NDOH 2012a:10). The NDOH 
envisages the NHMIS consisting of at least five key components: population-based 
information, health services based information, health resources records, vital 
registration data and finally transversal (government-wide) support systems (NDOH 
2012a:10). To develop such a system, the health sector would have to collaborate with 
other government departments such as the Home Affairs Department, Statistics South 
Africa (STATSSA) and private health sector organisations (NDOH 2012a:10). They 
would also have to liaise with the suppliers of the existing public sector health 
information systems currently in use in South Africa (NDOH 2012a:10). 
 
In order for the NDOH to deliver on the NHMIS strategy they would have to start 
developing the National Health Information Infrastructure (NHII). According to Detmer 
(2003:2), the NHII is the means by which the quality of health data, information and 
knowledge, used to support decisions at all levels and in all domains of the health 
sector, can be improved. Shortliffe and Cimino (2006:578) describe that the aim of a 
NHII is to provide access to anytime and anywhere health care information at the 
health facility level. To achieve NHII, electronic patient information needs to be 
collected and stored at each health facility (Shortliffe and Cimino 2006:485-486).With 
NHII, whenever a patient presents for care, the various existing electronic patient 
record systems can be located, collected, integrated, and immediately delivered to 
guide clinical decisions (Shortliffe and Cimino 2006:573). 
 
There are significant barriers and challenges to the development of NHII which include 
ensuring the confidentiality of electronic medical records, lack of interoperable 
standards for health information systems (HIS) data interchange, funding for health 
care information systems as well as legal and regulatory barriers (Shortliffe and Cimino 
2006: 575-576). Additionally an electronic health record system is not in place at every 
public health facility to provide the data to populate the NHIN. 
Despite the complexity and cost of developing an NHII, the long term goal for the 
NDOH would be to develop the required infrastructure to deliver on the NHMIS 
strategy. In summary the NHII has the potential to transform health care by improving 
health care quality, reducing health care costs, preventing medical errors, improving 
administrative efficiencies, reducing paperwork, and increasing access to affordable 
health care (Sittig, Shiffman, Leonard, Friedman, Rudolph, Hripcsak, Adams, 
Kleinman and Kaushal 2005:1). 
 
The majority of health facilities in South Africa would need to migrate to networked 
electronic patient record systems that would support HL7 data interchange and start 
using a national unique patient identifier to enable cohort analysis. Additionally the 
health care systems would need to be linked to systems such as the home affairs to 
validate national identity numbers. In South Africa it means that the health 
infrastructure would have to be substantially strengthened to support the NHII 
requirements for NHIN. 
 
2.7 Challenges with collecting ART data using paper based systems 
 
The quality of ART data collected for national priority programmes is critical as national 
policy changes are based on the analysis of the aggregated data reported by the DHIS. 
The decision by the national programme manager to increase the ART eligibility 
criteria, based on a CD4 count, must be based on good quality data. Incorrect 
decisions based on poor data could burden the entire public healthcare system. 
 
In 2009 Mate et al (2009:1) conducted a study to assess the completeness and 
accuracy of data reported for six key PMTCT data elements at health facilities in three 
districts in the KwaZulu-Natal Province. The study reported large variations in the 
completeness of data reporting for each of six PMCTC data elements on the DHIS 
(Mate et al 2009:3). The analysis of data accuracy for all six elements revealed that 
the clinic registers were missing data between 4.5% and 41.0% of the time (Mate et al 
2009:3). Their study highlighted the major flaws in the collection and reporting of 
PMTCT data at both the facility level (paper registers) and on the DHIS (Mate et al 
2009:4).  
Shortliffe and Cimino (2006:30-31) reported that any data collection system that relies 
on the manual capture of information onto datasheets that are later transcribed into 
computer databases for analysis, is both labour intensive and fraught with 
opportunities for error.  
 
Another study by Mate et al (2009:4) demonstrates how the data collection of a small 
subset of the DHIS national data elements can go wrong at the health facility level. 
Mate et al (2009:4) highlighted that even though the accuracy and completion of this 
PMTCT data was suboptimal, national health systems still use this data for national 
reporting and for financial allocations (Mate et al 2009:4).Additionally they found that 
data was frequently not submitted by health facilities to their local district office to 
capture into the DHIS, worsening the problem (Mate et al 2009:4). Similar problems 
with paper based systems have also been noted elsewhere. 
 
The Malawian Ministry of Health with partners conducted local supervisory visits in 
2006 to assess the completeness and accuracy of key case registration and outcome 
data compiled by 89 ART clinics in Malawi (Makombe, Hochgesang, Jahn, Tweya, 
Hedt, Chuka, Yu, Aberle-Grasse, Pasulani, Bailey, Kamoto, Schouten and Harries 
2008:311). The key case registration and outcome data was collected using the paper 
based WHO tools that are used for ART monitoring and consists of a master card for 
each ART patient and one patient register at each ART facility (Makombe et al 
2008:311), similar to data collection in South Africa. In their assessment of data 
quality, the study found that 70% of health facilities had complete data for the six key 
case registration fields (Makombe et al 2008:311) , but case registration data was 
accurate in only 40% of the health facilities. The study recommended moving to an 
electronic system to include mechanisms to improve quality of data, i.e. including using 
validation checks, bounds (range) checking and alerts (Makombe et al 2008:313). 
Several contributing factors including a higher work load, lack of dedicated data clerks, 
poor district supervision and poorly resourced facilities were identified (Makombe et al 
2008:311). 
 
A data quality improvement intervention was conducted in 2008 that included three 
main components; training on data collection, monthly review of data and data audits 
at individual facilities (Mphatswe Mate, Bennett, Ngidi, Reddy, Barker and Rollins 
2011:4). Data completeness improved from 26% to 64% following the intervention, 
This study highlights that with proper supervision and support it is possible to improve 
data quality using paper based registers (Mphatswe 2011:6). 
 
The challenges with collecting ART data using paper based systems include low levels 
of incompleteness and inaccuracy. Where countries have the resources and skills to 
implement electronic data systems, substantial improvement in data quality can be 
expected. Shortliffe and Cimino (2006:89) states that not only will electronic data 
collection systems improve data quality, they also make it feasible to monitor the data 
collected, generate warnings or advice based on either a single observation or for 
logical combinations of observations, provide automated quality control that include 
flagging potentially erroneous data and providing feedback on patient-specific or 
population based deviations from desirable standards. 
 
The additional limitation of paper based records is that the concentration of information 
is at a single location, which is at the health facility (Shortliffe and Cimino 2006:262). 
According to Shortliffe and Cimino (2006:262) this limitation prohibits the simultaneous 
entry and access of the information by multiple users. 
 
In summary, while paper based system can be used to collect national data for ART 
management, there are significant challenges to collating this data at health facilities 
and aggregating this information at the district, provincial and national level using the 
DHIS. Additionally the challenges related to ensuring data quality makes it difficult at 
the national level to accurately allocate human and financial resources.   
 
2.8 Challenges with collecting ART data using electronic medical record systems 
 
There are many challenges in a developing country for establishing electronic medical 
record systems as described by Sood, Nwabueze, Mbarika, Prakash, Chatterjee, Ray 
and Mishra (2008:3). Some of the factors to consider when implementing electronic 
medical record systems in developing countries include security, confidentiality, 
reliability, technical infrastructure, accessibility, interoperability, cost, language and 
culture (Sood et al 2008:6-7).  
 
The study by Forster, Bailey, Brinkhof, Graber, Boulle, Spohr, Balestre, May, Keiser, 
Jahn and Egger (2008:939) between 2006 and 2007, reviewed the use of electronic 
medical record systems in ART programmes in 15 countries in Africa, South America 
and Asia. Of the 21 health facilities surveyed only 18 routinely used an electronic 
database (Forster et al 2008:941).In 89% of these sites the clinicians used written 
charts during patient consultations that were then manually data captured (Forster et 
al 2008:941). The study assessed the percentage of missing data from the electronic 
medical record systems. They calculated a “missing data index” as the median of the 
percentages of missing data for six key variables that included the baseline and follow-
up CD4 counts (Forster et al 2008:941). The missing data index for the study was 
10.9% (Forster et al 2008:943). For the baseline CD4 percentage this missing data 
index increased to 19.8% (Forster et al 2008:943). 
 
The study also highlighted that most of the databases used rely on software intended 
for personal or small business use and could not meet the data needs as the patient 
numbers increased exponentially (Forster et al 2008:943). Medical Record 
applications such as tier 2 of the tiered ART M&E framework are based on a non-
networked Microsoft Access application with limited scope for growth.  
 
The review of ICT used in South Africa for HIV/AIDS and antiretroviral treatment by 
Sorensen, Rivett and Fortuin (2008:39) in 2006 highlighted universal issues regarding 
the use of electronic medical record systems in South Africa prior to the decision to 
move to the tiered ART and evaluation framework (Sorensen et al 2008:39-40). One 
of the challenges noted by the study was that the implementation and support of health 
systems in South Africa is managed at a provincial level, which has resulted in different 
provinces implementing different systems based on their specific requirements 
(Sorensen et al 2008:39).The study also concluded that with the exception of the major 
Health Information System (HIS) or Electronic Health Record (EHR) systems none of 
the other ICT systems were ready to be deployed in the country as a whole (Sorensen 
et al 2008:39).The study concluded that paper based and ICT systems would still 
coexist in South Africa for some time (Sorensen et al 2008:39). 
 
A major challenge for the tiered ART M&E strategy is that most health facilities have 
implemented tiers 1 and 2 (Magoro 2012). This leaves the majority of South African 
health facilities using either paper based standardised stationery (Tier 1) or non-
networked Microsoft Access based electronic records (Tier 2). Until the majority of 
health facilities offering ART services have transitioned to Tier 3, the full benefits for 
tiered ART M&E strategy will not be realised. 
 
2.9 Using ART data collected on the DHIS to plan and manage health facilities 
 
Garrib et al (2008:550) investigated the functioning of the District Health Information 
System (DHIS) in 10 clinics rural northern KwaZulu-Natal. There was good 
understanding of the data collection and collation process but little analysis, 
interpretation or utilisation of data (2008:550). In the 10 clinics, only 2.5% of indicator 
data values were missing (Garrib et al 2008:551). The study found that despite 
adequate training of the DHIS, health care workers and managers were not putting the 
data collected to good use (Garrib et al 2008:551). Several factors that affected the 
utilisation of DHIS data were identified. Some of these factors included poor skills 
transfer, high staff turnover and poor understanding of indicators (Garrib et al 
2008:551). This study highlights the importance of moving the emphasis with 
electronic medical record system from data collection and reporting, to the utilisation 
of data for decision making. 
 
2.10 The laboratory register 
 
Where electronic medical record systems are not in place, the health authorities have 
no option but to rely on aggregate district based reporting using standardised clinical 
stationery and the DHIS. Where electronic medical record systems are in place the 
collection of data is much easier.  However, the significant challenges with paper 
based and electronic medical record systems mitigate for the use of a laboratory 
register as an additional source of data to improve to quality of national reporting. The 
studies that will be discussed in this section demonstrate the usefulness of a laboratory 
register as an additional source of data as described in the conceptual framework. 
 
In a retrospective study by Morrow, Munro, Wilke, Stark and Wood (2012:501) data 
was collected from 17 clinics in South Africa that included laboratory test data as well 
as clinical and demographic data files and regimen information. The patients in the 
data sets were matched using a patient identification number. Each patient’s latest 
HIV Viral Load and CD4 prior to ART initiation were extracted. Additionally, the 
patients CD4 and HIV Viral Load results for routine ART monitoring were also included 
in the extract (Morrow et al 2012:502). 
 
The authors stated that there were many advantages to using laboratory data as the 
data is collected at a more centralised location (such as the NHLS CDW), and can be 
accessed as a single download as opposed to collation of monthly or quarterly records 
from the DHIS (Morrow et al 2012:503). Laboratory results are reliable as they are 
used in clinical practice that has the required quality control in place to ensure data 
consistency and accuracy (Morrow et al 2012:503). 
 
This study highlighted that it is possible to combine clinical and laboratory data using 
the patient identification number. This allowed the researchers to study the testing 
population. According to Shortliffe and Cimino (2006:517-518) the computer-based 
master patient index (MPI) is used to store patient identification information and basic 
demographic data that are acquired during the patient registration process, and simple 
encounter-level information such as dates and locations where services were 
provided. In South Africa where the majority of health facilities do not use a MPI system 
to ensure unique patient identification, one would have to resort to using probabilistic 
patient matching to achieve similar results. 
 
The laboratory register concept was first introduced for TB microscopy testing as part 
of the essential set of TB M&E data to be recorded. In 1998 the WHO introduced the 
concept of a laboratory register for TB testing (WHO 1998:25).The TB laboratory 
register is a record book maintained by the technician or technologist at the laboratory 
that is responsible for performing TB testing (WHO 1998:25). For each tuberculosis 
suspect identified by the laboratory the tuberculosis laboratory register records the 
patient’s demographic details (name, folder number, age, gender), date when the test 
was performed, smear and culture results as well as the results of confirmatory tests 
for M. Tuberculosis (WHO 1998:25). The latest requirements for a TB laboratory 
register brought the recording and reporting forms into line with the revised 2013 case 
and treatment outcome definitions (WHO 2013a:1).  
 
A retrospective study conducted by Mabaera, Lauritsen, Katamba, Laticevschi, 
Naranbat and Rieder (2008:294) collected data using TB laboratory register records 
for one calendar year from laboratories in Moldova (n=23), Uganda (n=30), Zimbabwe 
(n=23) and Mongolia (n=31). The TB laboratory register records were reviewed for 
completeness of recording age, gender and reason for examination (Mabaera et al 
2008:294). Based on the data collected, the study authors concluded that surveillance 
of some of the basic laboratory indicators could provide a simple and locally based 
adjunct to the improvement of the TB laboratory network (Mabaera et al 2008:299).The 
study found that the information recorded in the TB Laboratory Register not only 
identified weakness and strengths in the laboratory, it also revealed weakness on a 
much broader scale in the TB control programme (Mabaera et al 2008:294). 
 
The study highlighted the quality of data capture in four countries that attest to the very 
strong quality control over the collection and reporting of laboratory data. Laboratory 
staff is taught to work to very prescriptive standard operating procedures (SOP). 
 
A study conducted by Botha, den Boon, Lawrence, Reuter, Verver, Lombard, Dye, 
Enarson and Beyers (2008:936) tested the hypothesis that the use of the TB laboratory 
register would identify the deficiencies in case detection among adults in a high TB 
incidence area in the Western Cape province (Botha et al 2008:959). This study 
compared data extracted from the NHLS LIMS and paper-based facility registers. 
Botha et al (2008:938) reported that of the 367 TB cases identified (by the laboratory 
registers) only 303 (83%) were recorded in the routine facility TB treatment register. 
 
The benefits of using laboratory data is that it can utilise data stored on the LIMS, to 
generate the laboratory register to enable the health facility to correlate against data 
captured from paper-based register. An additional benefit would be the centralised 
storage of this data from each of the NHLS laboratories at the CDW would allow for 
the distribution of this data at the national, district, sub-district and health facility levels.  
 
2.11 Development of a national laboratory based data repository 
 
The NHLS developed a single national repository of all laboratory data within its 
Corporate Data Warehouse (CDW) making it possible to review public health 
laboratory data in South Africa. This has resulted in, for example, all public health 
sector CD4 laboratory data at the specimen level being available for extraction, 
analysis and reporting through the CDW (Grimett 2012). The specimen level data 
collected at the CDW includes information provided on the laboratory request form 
such as the patient demographic details and detail about the health facility requesting 
the test (Grimett 2012). This information is captured using the Laboratory Information 
Management Systems (LIMS) used at each NHLS laboratory (Grimett 2012). Each 
specimen is allocated a unique laboratory number. The LIMS then links the test results 
generated in the laboratory with the registration information captured from the 
laboratory request form using the laboratory number (Grimett 2012). The data 
collected by the LIMS at 265 laboratories within the NHLS network is consolidated at 
the CDW into a single national laboratory data repository (Grimett 2012). When the 
LIMS data reaches the CDW it is organised into logical reporting areas and structured 
according to data warehousing norms for reporting (Grimett 2012). This entire process 
is illustrated in Annexure D (Page 110).  
 
In the NHLS annual report for the financial period 2010/11, it was stated that the 
function of the CDW is to support the information needs of the NHLS and that of the 
Information Management Unit (IMU) (NHLS 2011:14). The CDW team enhanced the 
provision of information to the NDOH by continued development of reporting to support 
the National Priority Programmes (NHLS 2011:30). This included the TB multidrug-
resistant registers and early diagnosis of HIV infection in infants at 6 weeks. Monthly 
management summary reports by facility and province have been developed and are 
automatically circulated to the relevant recipients (NHLS 2011:30). 
 
The ability of the NHLS to collate near real time data from each of the NHLS 
laboratories (n=265) using the LIMS makes this a perfect platform to pilot the collection 
of the CCMT programme status information. Not only can this be included for reporting 
for the NDOH, this information can also be delivered electronically via a data interface 
to the multiple electronic medical record systems in use in South Africa.  
 
The feature to feed laboratory data back to electronic medical record systems from the 
CDW has already been demonstrated. In the NHLS Annual Report for the financial 
period 2010-2011 the CDW unit states that in providing automated data interfaces to 
patient management systems to facilitate improved patient care, the CDW continued 
to interface data daily to the WamTech TB Electronic Drug Resistance system 
(EDR)(NHLS 2011:30). An interface to the Therapy Edge Patient Management 
System has been developed to provide a daily transfer of test results back to health 
facilities (NHLS 2011:30).  In collaboration with the Desmond Tutu Tuberculosis 
Centre, an interface has been developed to transfer TB patient results to a patient 
management system developed for Cape Town City Health (NHLS 2011:30). 
 
The development of a CDW that integrates all LIMS data within the NHLS can become 
the first step in the development of an NHIN in South Africa. As the tiered ART M&E 
strategy evolves to a stage where most health facilities are using Tier 3, the ability to 
deliver near real-time laboratory data to the NHIN and EHR systems becomes critical. 
 
2.12 Conclusion 
 
In this chapter, the tiered ART M&E framework, paper based pre-ART register, 
laboratory register, laboratory data repository, development of a NHIN in South Africa 
as well as challenges with using and implementing paper based and electronic M&E 
systems were explored. The available literature reviews the national initiatives to 
introduce an integrated national M&E data system for South Africa. To achieve this 
NDOH set a goal to integrate health record systems in South Africa by bringing 
together all the different health information systems facilitating access to health 
records within a province and across provinces through the NHIN (NDOH 2008:7). 
 
The tiered ART M&E framework is an innovative system that will allow South Africa to 
migrate health facilities from paper based records to a non-networked M&E system 
and finally to a fully networked and integrated patient record system that could lay the 
foundations for an electronic health record. The inaccessibility of paper based M&E 
systems as well as the poor quality of data has been described. There are many 
challenges that need to be faced when implementing electronic M&E systems in 
developing countries. The complexity of provincial budgeting for IT expenditure also 
makes it difficult to standardise electronic patient record systems. Developing a NHIN 
to integrate all health record data from source systems brings about challenges of 
confidentiality of data, developing data standards and funding to develop health IT 
infrastructure. 
 
The use of laboratory registers where data from the LIMS is integrated into a national 
data repository hold great promise to provide national M&E data from a single data 
system. One of potential benefits of the laboratory registers is the ability to either 
replace or complement paper based and electronic M&E systems. When the final tier 
of the tiered ART M&E strategy is realised the ability to deliver laboratory results at the 
point of care in a comprehensive patient record offers the greatest potential to deliver 
on the NHIN strategy. 
 
The next chapter describes the research design and methodology employed for the 
research study. 
CHAPTER 3: RESEARCH DESIGN AND METHOD 
 
3.1 Introduction 
 
This study is a health systems research study aimed at developing new systems to 
deliver improved CD4 reporting with a CCMT patient programme status for better 
programme management. 
 
3.2 Study Design 
 
According to Eng and Siegelman (2007:653) the definition of the study design is a 
multi-step process that starts with defining a target population, i.e. the population for 
whom the study is intended. The next step is the definition of inclusion and exclusion 
criteria to specify who from the target population will be considered for the study (Eng 
and Siegelmen 2007:653).  
 
The design of the study was descriptive (designed to describe and explore attributes) 
and cross-sectional (data collection was done once only).  Descriptive designs are 
employed in studies where additional information is required in a particular field 
through the provision of a picture of the phenomenon as it occurs naturally (Brink, van 
der Walt and van Rensburg (2012:112).  The additional question for the study was the 
CCMT programme status. Cross sectional studies are used to examine data at one 
point in time (Brink et al 2012: 115). For the study data was collected once only using 
the new CCMT request form. 
 
3.3 Target population 
 
The target population included patients who attended health facilities for CD4 testing 
in the Ekurhuleni health district.  
 
3.3.1 Sampling Frame 
According to Brink et al (2012:132), the sampling frame is a comprehensive list of 
sampling elements in the target population. For the study the sampling frame was 
hospitals within the Ekurhuleni health district. 
 
3.3.2 Description of the study area 
 
The map below depicts the borders of the Ekurhuleni health district. This district is one 
of six districts in the province of Gauteng. Ekurhuleni is Tsongo word which means a 
“place of peace” (About Ekurhuleni: 2012). The district is subdivided into four health 
sub-districts, viz. East, South, North and West. The district has a population of 
approximately 2.4 million (About Ekurhuleni: 2012) people served by four regional 
hospitals, one district hospital, and 99 primary health care (PHC) clinics (Magoro 
2012). 
 
Source: (MDB 2013) 
Figure 3.1: Map showing Ekurhuleni health facilities      
3.4  Study population 
 
The study population were patients who attend the Tambo Memorial, Far East Rand 
and Tembisa HIV clinics and who required CD4 testing in the Ekurhuleni health district, 
based in the towns of Boksburg, Springs and Tembisa respectively. All have busy ART 
and HIV counselling and testing wards. According to the DHIS classification, all three 
study sites are classified as regional hospitals (NDOH 2012c:36).  
 
3.4.1 Selection of Study Population 
 
A simple sequential sampling of public sector health facilities in the Ekurhuleni health 
district was undertaken using the CD4 test volume for 2011 from the NHLS Corporate 
Data Warehouse. The annual CD4 test volumes for this period was ordered in 
descending order, and the top three health facilities were proposed and adopted for 
study in consultation with the Gauteng Department of Health. 
 
3.4.2 Inclusion Criteria 
 
The inclusion criteria was also utilised to limit the study to a specific geographic area 
and time period. The table below describes the inclusion criteria for the study: - 
 
Table 3.1: Inclusion criteria for study 
Inclusion Criteria Rationale 
Patients between 18 years and 
older.  
The study investigated the collection of the programme 
status for adults. 
Patients presenting for CD4 testing 
at the Tambo Memorial, Far East 
Rand and Tembisa study sites. 
The three study sites are based in the Ekurhuleni health 
district and were selected based on submitting the highest 
number CD4 samples per month in the 2011 calendar year 
(Coetzee 2012). 
CD4 sample received on the new 
CCMT request form(Form 4 page 
96) 
The study collected data using the new CCMT request 
form (Form 4 page 96). The barcode sequence was used 
to identify CD4 results received on the new CCMT request 
form. 
 
  
Inclusion Criteria Rationale 
Study Period: 1 October 2012 to 
31 January 2013 
Based on the number of samples submitted per day in 
2011 by the three health facilities, the study was 
planned for one month (Coetzee 2012). However, the 
study was conducted for four months in order to reach 
the required sample size. Due to the implementation of 
HIV and ART services to the surrounding PHC facilities 
the study took longer to complete 
CD4 sample request following 
HCT or for routine ART 
monitoring 
The patient would be identified for CD4 testing 
following a positive HIV rapid test during HCT or during 
routine ART monitoring. Current ART guidelines 
prescribe CD4 testing following a positive HIV rapid 
test (NDOH 2010:3) 
 
3.4.3 Exclusion Criteria 
 
The table below provides a list of exclusion criteria as well as the rationale for each: - 
 
Table 3.2: Exclusion criteria for study 
Exclusion Criteria Rationale 
CD4 samples that are 
received on the existing 
CCMT request form (Form 
3 Page 95). 
Al CD4 samples received on the Existing CCMT request form 
(Form 3 Page 95) were excluded from the study. This form 
uses a specific barcode sequence, e.g. ASFD1234B. 
CD4 samples from other 
health districts in Gauteng 
received at the CD4 
laboratories in the 
Ekurhuleni health district 
Any CD4 samples received from outside the Ekurhuleni 
health district, tested at CD4 laboratories within the 
Ekurhuleni health district, were excluded (outside target 
population). Each CD4sample recorded on the LIMS had a 
dedicated location code for the health facility, e.g. TEM for 
Tembisa Hospital. The specific location codes were used to 
identify study data from the three study sites. Additionally, the 
three location codes were used by the CDW to extract data 
for the study (refer to Annexure F Page 127). 
   
3.4.4 Method of selecting health facilities 
 
The health facilities were selected in conjunction with Gauteng provincial CCMT Unit 
as well as the Ekurhuleni district health management after reviewing the 2011 CD4 
test volumes. The three study sites were selected on the basis that they provide HIV 
and ART services, are situated within 100km of an existing NHLS CD4 testing 
laboratory, are already using the Existing CCMT request form (Form 3 Page 95) and 
submitted over 600 CD4 samples on average per month on average in 2011.  
 
3.4.5 Method of selecting sample 
 
For selecting the study sample, non-probability sampling was utilised to identify the 
health facilities where the study was conducted. For the selection of patients, 
convenience sampling was utilised as the patients (study subjects) would be attending 
the health care facility for routine HIV services making them easily accessible for the 
study. Convenience sampling is easy, fast and the least expensive sampling 
technique. However one of the weaknesses of convenience sampling is that sampling 
bias is likely to be introduced to the study. The sampling frame for this study would be 
the hospital, i.e. the three regional hospitals selected in the Ekurhuleni health district. 
 
 
3.4.6 Size of sample 
 
It is important to take into consideration the size of the sample required to achieve the 
study aims. The calculation of the sample size is determined by three main factors; p-
value, statistical power and the size of the effect to be detected (Whitley and Ball 
2002:336).Additional factors that must be taken into consideration when deciding on 
a sample size for a research study are: - 
 Level of accuracy required 
 Size and heterogeneity of the population 
 Nature of the research design, e.g. qualitative or quantitative 
 Financial resources 
 
The use of the macorr sample size calculator (http://www.macorr.com/sample-size-
calculator.htm) is recommended by Brink et al (2012:143). To compute the study 
sample size the following values were provided: - 
  
Table 3.3: Variable used in the Macorr Sample Size Calculator 
Variable Value Description 
Population Size 16892 The population size is the average number of CD4 tests 
received per month from the Ekurhuleni health district during 
the calendar year 2011. 
Percentage 50% The worst case percentage of 50% was entered on the 
sample size calculator for the percentage of samples that 
did not tick the programme status box. According to the 
Macorr sample size methodology, when determining the 
sample size needed for a given level of accuracy one should 
use the worst-case percentage (50%). 
Confidence 
Interval 
2.7% The confidence interval of 2.7% was used. 
Confidence Level 95% The confidence level of 95% was used. 
 
 
Source: http://www.macorr.com/sample-size-calculator.htm 
Figure3.2: Output from the Macorr Sample Size Calculator 
 
An adequate sample size as well as the appropriate research design are critical in 
allowing the study results to be generalised to the target population (Joubert and 
Ehrlicht 2009:94). 
 
The sample size for the research study was calculated as 1200 by the macorr sample 
size calculator based on the values from table 3.3. Of the sample size of 1200, 500 
samples were allocated to the Tambo Memorial study site. The Far East Rand and 
Tembisa study sites were allocated 350 samples each.  
3.5 Data sources 
 
A number of data collection methods as well as data collection instruments are used 
for this study. 
 
3.5.1 Data collection Methods 
 
The following data collection methods were employed for this study:- 
 New CCMT laboratory request form (Form 4 page 96) 
 Interview with professional nurses and clinicians 
 Interview with laboratory staff at the week follow-up visits 
 Self-administered pre-ART register questionnaire (Form 5 page 97) 
 
3.5.2 Data collection instruments 
 
A number of data collection instruments are used for this study. They are listed below 
in chronological order: - 
 New CCMT Request Form pre-testing questionnaire (Form 1 page 91) 
 Site follow-up visit form(Form 2 page 93) 
 Existing CCMT request form(Form 3 Page 95) 
 New CCMT request form (Form 4 page 96) 
 Pre-ART laboratory register questionnaire (Form 5 page 97) 
 
3.5.2.1 New CCMT Request Form pre-testing questionnaire (Form 1, page 91) 
 
The reason for pre-testing a new data collection instrument for this research project 
was to evaluate whether the respondents interpret questions in a consistent manner 
as intended by the researcher. The pre-testing of the New CCMT Request Form (Form 
4 page 95) involved asking the selected health care workers to review the form with 
regard to its flow and ease of completion.  
 
3.5.2.2 Site follow-up visit form (Form 2, page 93) 
 
In weeks two, four and seven of the study, the laboratories and study sites were visited 
to review progress. At the laboratory the percentage of CD4 requested forms 
completed with the required information were assessed. Additional aspects assessed 
included the form legibility, data capture accuracy and awareness. The follow-up visit 
forms (Form 2 page 93) were completed by the researcher based on the findings of 
the visits.  
 
3.5.2.3 Existing CCMT request form (Form 3 Page 95) 
 
The existing CCMT request form implemented by the NHLS in 2009, used by health 
facilities in the Ekurhuleni health district, forms part of the pre-study baseline data 
analysis. This laboratory request form is completed by health care workers at the 
health facilities and sent to their local CD4 laboratory. 
 
3.5.2.4 New CCMT request form (Form 4, page 96) 
 
The new CCMT request form design was based on the existing CCMT request form 
(Form 3 Page 95), and amended to meet the new HIV and TB programme status 
reporting requirements incorporate the current HIV and AIDS guidelines and reflect 
CCMT programme status. This new form is divided into multiple sections that are 
provided to capture the health facility details, patient demographics, specimen details, 
clinical information, laboratory tests requested and the CCMT programme status data 
collection tool. For the study, the new CCMT request form (Form 4 page 96) was used 
to collect the programme status for CD4 samples. 
 
3.5.2.5 Pre-ART laboratory register questionnaire (Form 5 page 97) 
 
This form was administered at the end of the study after the pre-ART register had been 
delivered by the researcher to the health facility manager. It was designed to be a self-
administered questionnaire that consisted of two sections. The first section assessed 
the quality and format of the laboratory-based pre-ART register. The second section 
assessed whether the laboratory based pre-ART register could reduce pre-ART loss 
to follow-up and improve record management and DHIS reporting.  
 
3.6 Data Collection 
 
The data for the study was collected using the forms described above and collected in 
a two-step process. In step one, the new CCMT laboratory request form (Form 4 page 
96) was used by the health care worker to capture information about the health facility 
where the CD4 test originated, the patient’s details, laboratory tests required and the 
CCMT programme status. In step two, the completed request forms (Form 4 page 96) 
were delivered with the patient’s blood samples to the local laboratory where a 
laboratory data capturer would enter the information on the Disa*Lab Laboratory 
Information Management System (LIMS). Prior to the data collection, training was 
provided to the study sites and laboratory data capturers on data collection tools used 
in the study. Follow-up visits were conducted at week two, four and seven at the CD4 
laboratory to assess the quality of data provision by the study sites and data capture 
at the laboratories. The findings of the follow-up visits were collected using the site 
follow-up visit form (Form 2 page 93). 
 
Throughout the study data from the individual laboratories (LIMS) were replicated to 
the Corporate Data Warehouse (CDW) at the NHLS via wide area network (WAN). In 
this way the data collected for the study was routinely monitored. 
 
3.6.1 Data collection method 
 
The selection of the method for the data collection depended on a number of factors. 
The two key factors in making this decision were the information required to achieve 
the study objectives and the resources available. 
 
 
3.6.2 Development and testing of the data collection instrument 
 
The primary data collection instrument, i.e. the new CCMT request form (Form 4 page 
96) was developed the NHLS in collaboration with Western Cape HIV clinicians and 
the Western Cape laboratory co-ordinator. This document was distributed by the 
NDOH Laboratory Co-ordinator to provincial laboratory co-ordinators, NDOH priority 
programme units (HIV & TB) and within the NHLS (refer to Annexure C) for additional 
input and approval. 
 
The purpose of pre-testing the data collection instrument was to detect any possible 
flaws such as ambiguous instructions or wording and to determine whether the 
respondents understood what is required of them.  The pre-testing was conducted on 
full time employed phlebotomists at the Charlotte Maxeke Johannesburg Academic 
Hospital (CMJAH) main blood room. This facility sees patients from the many wards 
at CMJAH for venepuncture and was selected because of their extensive exposure to 
the existing NHLS request forms.  
 
3.6.3 Data collection process 
 
After pre-testing, the pre-study baseline data was extracted using the existing CCMT 
request form (Form 3, page 95) prior to training the health facility on the new CCMT 
request form. This was done to assess the comprehensiveness and quality of data 
using the existing CCMT request form (Form 3 Page 95). By using the sequence of 
the barcode (e.g. ABCD 1234 B) on the existing CCMT request form, the number of 
CD4 samples received with a programme status was assessed. 
 
 Follow-up visits were conducted to review the data collected. Following the 
completion of the study, the CD4 and CCMT programme status data from the 
individual laboratories was extracted by the Corporate Data Warehouse (CDW) and 
analysed using Stata and Excel.  
 
3.6.4 Ethical considerations related to data collection 
 
The following ethical considerations apply to data collection. They are organised by 
the most common categories of responsibility that a researcher must comply with 
(Annexure M Page 161).  
 
3.7 Reliability and validity of data sources 
 
3.7.1 Reliability 
 
The reliability of the research instrument used for the study can be assessed by the 
degree to which the instrument can be depended upon to yield consistent results if 
used repeatedly over time (Brink et al 2012:169). Reliability can be characterized by 
stability, internal consistency and equivalence reliability (Brink et al 2012:170).The 
following measures were taken in the design of the new CCMT request form (Form 4 
page 96) to ensure that the data collection instrument could be relied upon to produce 
consistent results if used repeatedly:- 
 The form was divided up into groups that collected data about a particular 
variable. For example the “LOC” box on the new CCMT request form was 
designed to collect information about where the sample originated. This design 
method was employed to ensure that each box or section on the new CCMT 
request form collected data about a specific group of variables. The flow from 
one box/section to the next was also designed to offer the user a logical flow 
for completing the form. 
 
3.7.2 Validity 
 
The validity of the data collection tool seeks to determine whether the instrument 
accurately measures what it is supposed to measure (Brink et al 2012:165). There are 
four common types of instrument validity; content validity, face validity, criterion-
related validity and predictive validity (Brink et al 2012:166-167). The researcher used 
content validity to assess the data collection instrument. The content validity is an 
assessment of how well the data collection instrument (new CCMT request form) 
represents all the components of the variables to be measured (Brink et al 2012:166). 
The following measures were taken in the design of the new CCMT request form to 
ensure that the data collection instrument measures what it purports to measure: - 
 The CCMT programme status options for a CD4 test are mutually exclusive, 
which makes the data collection instrument more reliable, e.g. reduces the 
possibility of receiving two CCMT programme status values for a CD4 sample. 
 Each programme status option was captured on the Disa*Lab Laboratory 
Information Systems (LIMS) to collect data in a standardised format, i.e. to 
avoid free-text entries. 
 
These measures ensured that the data collection instrument (i.e. new CCMT form) is 
reliable. 
 
3.7.2.1 Internal Validity 
 
Internal validity relates to the degree to which the researcher has managed to 
eliminate confounding variables in the research design (Brink et al 2012:127). This 
study is a health systems research study aimed at evaluating whether the addition of 
a single new parameter, i.e. the programme status data on the NHLS request form 
can provide programmatic M&E data for meaningful application in the CCMT 
Programme. As such the study will use data collection instrument (i.e. laboratory 
request form completed by attending health care workers who collect the routinely 
requested CD4 sample from the patient. The following precautions were taken during 
the design of the study to improve the internal validity of the research design: - 
 Use of a standardised data collection tool (new  CCMT request form) 
 Data collection was assessed through follow-up visits. 
 
3.7.2.2 External Validity 
 
A study that readily allows its findings to generalise to the population at large has high 
external validity (Brink et al 2012:111). The following precautions were taken during 
the design of the scientific study to improve the external validity of the research design: 
- 
 The health care workers providing the CCMT programme status were trained 
prior to the study to ensure accurate and comprehensive provision of the CCMT 
programme status for CD4 testing. 
 The new CCMT request form (Form 4 page 96) was developed following 
extensive consultation within the NHLS and the National Department of Health. 
Additionally the Virology Expert Committee, within the NHLS, validated the 
design of the data collection tool. 
 
3.8 Bias and limitations 
 
Bias is defined as an influence that can produce an error or distortion of the study 
results and can affect the quality of evidence in both qualitative and quantitative 
studies (Brink et al 2012:98).  
 
Selection bias is introduced into a study when there are systematic or directional errors 
in how participants are sampled  Selection bias in a study results in the study sample 
being systematically different from the population they were drawn from (Joubert and 
Ehrlicht 2009:160).  Random selection and assignment or matching in the study design 
stage can decrease the potential for selection to be a threat to validity (Brink et al 
2012:111).  
 
Information bias occurs when systematic or directional bias in how measurements are 
collected from participants in the study (Joubert and Ehrlicht 2009:163). An important 
step in reducing information bias is to ensure that variables are measured in the same 
way for all participants (Joubert and Ehrlicht 2009:163).  
 
The following measures were taken to reduce bias for this study – 
 The study sites were provided with standardized operating procedures (SOP) 
for completing the new CCMT request form (Form 4 page 96). The laboratory 
data capturers captured the information provided on the data collection 
instrument directly on the Laboratory Information management System (LIMS).  
 Additional onsite training with standardised training guides was provided to the 
study sites to further reduce data capture variability. 
 To minimise selection bias for the study, sequential sampling of health facilities 
was utilised. It was not anticipated that this method of sampling would bias the 
outcomes of the study. 
 Through the use of the LIMS, data was captured in parameters that were 
specifically designed to include data validation checks. Additionally 
standardised LIMS codes were programmed into the parameter dictionary to 
limit what could be captured to a select list of programme status options. 
 The results of the study were triangulated with other data sources. The CD4 
test ranges for the study were triangulated with the national CD4 data reported 
from the CDW. Additionally age range reported for the study were triangulated 
with STATSSA published data.  
 
3.8.1 Limitations of the study 
 
This study is limited to hospitals based in the Ekurhuleni health district and may 
therefore not be generalised to the broader primary health care clinics in this district 
or broader application. In reality the ongoing intervention and training may not occur 
when implemented in other districts. It may therefore be difficult to generalise the 
findings of the research study. 
 
3.9 Data analysis 
 
The CD4 programme status data was extracted from the CDW using the Aginity 
workbench for Netezza tool. The data model in Annexure D describes the flow of 
information from the LIMS at the local laboratories to the CDW. The study data was 
analysed using Excel and Intercooled Stata 11.The data analysis included reporting 
the following data; median CD4 for pre-ART and ART programme status, percentage 
of CD4 samples in the pre-ART and ART programme status categories, percentage 
accuracy of pre-ART electronic register (compared to paper based pre-ART register) 
and proportion of patients about to start ART with a CD4 count below 50 cells/µl. 
 
3.10 Conclusion 
 
This chapter provided a detailed description of the study methodology used. The 
ethical considerations relating to reliability, validity of the data and data collection 
instruments (CCMT forms) have been discussed. The next chapter will describe the 
results obtained from the analysis of the various sources of data.  
 
CHAPTER FOUR: ANALYSIS, PRESENTATION AND DESCRIPTION OF THE 
RESEARCH FINDINGS 
 
4.1 Introduction 
 
This chapter outlines the research findings of the study. Data is presented by means 
of tables, graphs and histograms. The results are reported for the pre-testing, pre-
study data analysis as well as the data collected for the study using the new CCMT 
request form (Form 4 page 96). Additionally, the feedback received for the pre-ART 
register is reported.   
 
For the pre-study data collected using the existing CCMT request form (Form 3 Page 
95) was analysed for CD4 samples submitted from the three study sites. For the study 
the information provided on the new CCMT request form (Form 4 page 96) by the 
study sites was captured on the LIMS.  
 
The pre-study data analysis reports on the “as-is” data collection using existing 
systems. For the study the interventions included introducing a new request form, 
providing standardised materials and providing training.  
 
4.2 Research results 
 
The research results are presented under the following headings:- 
 Pre-testing (using Form 1 Page 91) 
 Pre-study baseline results (using Form 3 Page 95) 
 Study follow-up visit findings (using Form 2 Page 93) 
 Study results (using Form 4 Page 96) 
 Pre-ART register (using Form 5 Page 97) 
 
 
4.2.1 Pre-testing 
 
The results of the pre-testing presented below include an assessment of the reliability 
and validity of the data collection instrument (new CCMT request form). For the 
assessment of the reliability (repeatability) of the data collection instrument, the 
completed forms were reviewed to assess whether the phlebotomist provided the 
same programme status on the two completed new CCMT request forms. In the pre-
testing 75% of the phlebotomists provided the same CCMT programme status 
information (Figure 4.1). 
 
 
Figure 4.1: CD4 Programme Status reliability finding 
 
To appraise the validity of the new CCMT request form, the pre-testing assessment 
form was evaluated using a standardised questionnaire. All of the phlebotomists (n=8) 
found that the new CCMT request form was easy to understand and had a logical flow 
that was suitable for health care workers. Two issues were raised. Firstly the 
completion of ICD 10 code (International Statistical Classification of Diseases and 
Related Health Problems, e.g. E10 used for Insulin-dependent diabetes mellitus) may 
be difficult to understand and secondly, that the completion of the clinical information 
ideally should be provided by clinicians. These concerns were noted. However, both 
are routine requirements for NHLS request forms as well as being a requirement by 
the NDOH as a diagnostic coding standard (NDOH 2012b:5). For certain laboratory 
tests, such as tissue samples for microbiological testing, the clinical diagnosis should 
match
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be provided on the laboratory request form according to the NHLS laboratory 
handbook (NHLS 2012:80).Therefore it was decided to leave these two elements on 
the new CCMT request form (Form 4 page 96) to comply with current standards. 
 
The qualitative aspects highlighted by the phlebotomist provided in the more open-
ended questions such as “please add any other information you would like to highlight” 
about the new CCMT request form, included comments such as “it is good to have to 
show who has collected the specimen so that you can track back”, “the form is simple 
and straightforward” and “I am satisfied with the new CCMT form”. In summary the 
pre-testing confirmed that the new CCMT request form was acceptable and not likely 
to be ambiguous based on the subjective responses of the phlebotomists attending 
(Figure 4.2). 
 
 
Figure 4.2: Pre-testing assessment form response summary 
 
4.2.2 Pre-study baseline results 
 
Of the 3168 CD4 samples received, over 97% (n=3103) were requested on the 
existing CCMT request form (Form 3 Page 95). At the Far East Rand study site, of the 
863 existing CCMT request forms received (Form 3 Page 95), no CD4 samples had 
the CCMT programme status captured on the LIMS. In comparison, the Tembisa study 
site captured the CCMT programme status for 21.61% (n=250) of CD4 samples (Table 
4.1). It is not clear whether this is due to poor implementation of standard operating 
procedures (SOP) or due to health care workers not providing this information. The 
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Tambo Memorial site had the highest rate of programme status provision on the LIMS 
at 57.53% (n=623). Overall the baseline analysis indicates that the existing systems 
could provide data to support a CCMT programme status reporting system but that the 
cooperation and response of health care workers in filling in programme status on the 
form was generally poor.  
 
Table 4.1: (Baseline) CCMT Programme Status analysis on data entered on the existing NHLS 
request form 
 
 
The CCMT programme status values captured in the LIMS (using coded comments) 
were categorised as ART, Pre-ART or No Data Supplied (where no information was 
provided by the health care worker). Some of the values captured were categorised 
as excluded as they included drug and PMTCT codes. Most of the CCMT programme 
status captured on the LIMS were from the ART category (55.2%), followed by pre-
ART (33.9%). Only 6.7% of the data was categorised as excluded. Overall the CCMT 
programme status was provided by health care workers and captured on the LIMS in 
only 27.56% (n=873) of CD4 samples where the old CCMT form was used (Table 4.3). 
The median CD4 for the ART category was 361 cells/µl compared to 196 cells/µl for 
the pre-ART category.  It was however not possible to identify the percentage of first 
ever CD4 samples for the baseline data as this information was not captured on the 
old CCMT form. For patients with a pre-ART CCMT programme status, 19% had a 
CD4 count below 50 cells/µl. 
 
Table 4.2: CD4 count median and proportion of CD4 samples <= 50 cells/µl for the CCMT 
programme status categories 
 
 
No Programme 
Status
Prog Stat 
Captured
Total % Captured
No Programme 
Status
Prog Stat 
Captured
FAR EAST RAND 863 863 0 9 872 27.53                  
TAMBO MEMORIAL 460 623 1083 57.53            10 5 1098 34.66                  
TEMBISA 907 250 1157 21.61            41 1198 37.82                  
Total 2230 873 3103 28.13            60 5 3168 100.00               
% Total 70.39                    27.56                   97.95 1.89                      0.16             100
% Grand Total
Other NHLS request form
Grand TotalHealth Facility
CCMT Form
ART 485 56          361           14          471           3%
PRE-ART 297 34          196           56          241           19%
NO DATA SUPPLIED 32 4            214           6             26              19%
EXCLUDED* 59 7            1 58
Total 873 100 77 796
>50 
cells/ul
% <= 50
* PMTCT and Drug codes
CCMT Programme 
Status Category
n=
Median 
CD4 
% Total
<= 50 
cells/ul
4.2.3 Study follow-up visit findings 
 
The new CCMT forms were delivered and training provided prior to the study. The 
research study commenced on 1 October 2013 and regular follow up visits were 
conducted to assess data provision. Follow up visits were conducted at weeks two, 
four and six. 
 
4.2.4 Study results  
 
At the follow-up visits, the number of new CCMT request forms received by the 
laboratory were manually counted. Additionally, the laboratory staff assessed the 
number of forms where the CCMT programme status was provided by the health care 
workers. Ten request forms were randomly selected by laboratory staff to assess 
whether the data capturers had entered the patients gender and programme status on 
the LIMS.  
 
4.2.5. Week two follow-up visit findings 
 
By the beginning of week two, 240 of the new CCMT request forms had been received 
for the study, the majority originating from the Tambo Memorial Site (66.67 %). Overall, 
at the time of the assessment, 20% of sample size had been achieved (Table 4.3). At 
the Far East Rand study site, most of the new CCMT request forms were received 
from the Osizweni ART ward, despite an agreement to distribute the request forms to 
other medical wards as well. The researcher informed Dr. Ncholo, who agreed to 
speak to other clinicians to start using the new CCMT request forms in the medical 
wards. The Tembisa and Tambo Memorial study sites did much better, as samples 
were received from the wards as agreed at the training sessions. The Tembisa study 
site agreed to increase the use of the new CCMT request form in other medical wards. 
It was noted that most of the new CCMT request forms originated from the Masakhane 
ART ward with only a few CD4 samples received from the medical wards. 
 
 
Table 4.3: Number of new CCMT request forms received per site at the beginning of week two 
Site Date Assessed n= % Total Target 
% of Sample 
Size 
Tembisa 09 October 2012 60         25.00  350                 17.14  
Tambo Memorial 11 October 2012 160         66.67  500                 32.00  
Far East Rand 09 October 2012 20           8.33  350                    5.71  
Total   240      100.00  1200                 20.00  
 
For this assessment of accuracy of the data captured, the laboratory staff randomly 
selected ten request forms and called up the LIMS registration screen for each 
laboratory number. Using a tick sheet, the laboratory staff placed a tick if the CCMT 
programme status provided on the new CCMT request form had been captured on the 
LIMS. The Tembisa and Tambo Memorial laboratories scored in excess of 90% for the 
random sample of ten request forms (Table 4.4). The Far East Rand site had not 
implemented the data capture requirements for the study despite receiving the same 
training as the other two laboratories. An intervention was planned for this laboratory 
with the acting laboratory manager to ensure that back capture was completed and 
that the information required was captured going forward. 
 
Table 4.4: Percentage compliance with providing and capturing CD4 Programme Status 
information in week two 
 
 
4.2.6 Week four follow-up visit findings 
 
By the beginning of week four, 613 new CCMT request forms (Form 4 page 96) had 
been received for the study, the majority originating from the Tambo Memorial study 
site (50.57 %). Overall, 51.08% of the sample size had been achieved (Table 4.5). At 
the Far East Rand study site, the new CCMT request forms were received from various 
medical wards in addition to the Osizweni ART ward. The Tambo Memorial study site 
had reached 62% of their required sample size compared to 54.86% for Tembisa and 
31.71% for the Far East Rand site (Table 4.5). This was a substantial increase from 
the two week follow-up visit where the sites had reached 32%, 17.14% and 5.71% 
respectively. 
Tembisa 09 October 2012 96.67                                              100.00                                        90.00                                                          
Tambo Memorial 11 October 2012 96.25                                              100.00                                        100.00                                                        
Far East Rand 09 October 2012 95.00                                              100.00                                        -                                                              
Total
% gender correctly 
captured in LIMS (n=10)
% CD4 Programme Status 
correctly captured in LIMS (n=10)Site Date Assessed
% Forms with CD4 
Programme Status Provided 
Table 4.5: Number of new CCMT request forms received per site at the beginning of week four 
Site Date Assessed n= % Total Target 
% of Sample 
Size 
Tembisa 24 October 2012 192     31.32  350              54.86  
Tambo Memorial 24 October 2012 310     50.57  500              62.00  
Far East Rand 24 October 2012 111     18.11  350              31.71  
Total   613  100.00  1200              51.08  
 
When comparing the accuracy of the data capture on the LIMS at the three 
laboratories at the week four follow-up visit, the Tembisa and Tambo Memorial 
laboratories scored in excess of 90%, compared to 30% at the Far East Rand 
laboratory (Table 4.6). However 90% of the Far East Rand new CCMT request forms 
had a CD4 programme status captured on the LIMS, just not in the correct parameter 
on the LIMS. The data capturers at this laboratory were offered additional onsite 
training to populate the LIMS parameter specifically designed for the study.  
 
Table 4.6: Percentage compliance with providing and capturing CD4 Programme Status 
information in week four 
 
 
4.2.7 Week seven follow-up visit findings 
 
A follow-up visit was planned for week six, however due to work commitments the 
researcher had to reschedule the follow-up visit to week seven. By the 16th of 
November 2012, 1037 forms had been received for the study, the majority originating 
from the Tambo Memorial Site (55.26%). Overall at the time of this assessment, 
86.42% of sample size had been achieved (Table 4.7). 
 
The Tambo Memorial site had reached 114% of their required sample size compared 
to 73.14% for Tembisa and 59.43% for the Far East Rand study site (Table 4.7). This 
was a substantial increase from the week four follow-up visit where the sites had 
reached 2%, 54.86% and 31.71% respectively. 
Tembisa 24 October 2012 192 31.32    350 54.86             96.88                       100.00                80.00                              
Tambo Memorial 24 October 2012 310 50.57    500 62.00             97.74                       100.00                90.00                              
Far East Rand 24 October 2012 111 18.11    350 31.71             98.20                       100.00                30.00                              
Total 613 100.00 1200 51.08             
% CD4 Programme 
Status correctly 
captured in LIMS 
(n=10)Site Date Assessed n=
% of 
Sample Size
% Forms with 
CD4 Programme 
Status Provided 
(n=60)
% gender 
correctly 
captured in 
LIMS (n=10)% Total Target
Table 4.7: Number of new CCMT request forms received per site at week seven 
Site Date Assessed n= % Total Target % of Sample Size 
Tembisa 16 November 2012 256     24.69  350                 73.14  
Tambo Memorial 16 November 2012 573     55.26  500              114.60  
Far East Rand 16 November 2012 208     20.06  350                 59.43  
Total   1037  100.00  1200                 86.42  
 
The figure below (Figure 4.3) demonstrates how the Tambo Memorial site accelerated 
the uptake of the new CCMT request form to reach 114.6% of the required sample 
size by week seven. In contrast, the Tembisa and Far East Rand sites displayed a 
much slower increase in the uptake of the new CCMT request form. Telephonic 
discussions were arranged with these study sites to discuss interventions aimed at 
improving capture of the relevant programme status data. This included extending the 
study period. 
 
 
Figure 4.3: Number of new CCMT request form received per site at each follow-up visit 
 
The assessment of the provision of the CCMT programme status information 
confirmed again that each study site provided the required information in 95% or more 
of all CD4 samples requested for the study (Table 4.8). The assessment of the data 
capture of the CD4 programme status information on LIMS confirmed that the three 
laboratories captured the required information in 70% or more of the CD4 samples 
requested for the study. 
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Table 4.8: Percentage compliance with providing and capturing CD4 Programme Status 
information in week seven 
 
 
4.2.8 Pre-ART register 
 
During the study, a pre-ART register was printed for each study site. An extract of the 
pre-ART register delivered to Tambo Memorial study site is included in Annexure J 
(Page 150). This register listed all CD4 samples that were received with a “First ever 
CD4” programme status and where the CD4 count was below 350 cells/µl. A self-
administered questionnaire was provided to the study sites to assess the laboratory 
based pre-ART register. Each study site was expected to review their laboratory based 
pre-ART register and complete the pre-ART questionnaire (Form 5 page 97) to assess 
the usefulness of the laboratory based pre-ART register. 
 
In the first section of the pre-ART questionnaire the study sites were requested to rate 
the format and the quality of the pre-ART laboratory register compared to their existing 
paper-based records.  The questionnaire utilised a five point scale to rate each 
question (excellent, very good, good average and poor). The responses were 
allocated a numerical score (1-5), with excellent scored as five and poor scored as 
one.  
 
All three study sites rated the quality and format of the pre-ART laboratory register a 
score of four or five (excellent or very good) (Figure 4.4). This confirms that the study 
sites were satisfied with the content and format of the pre-ART laboratory registers. 
Tembisa 16 November 2012 256 24.69    350 73.14                97.20                           100.00                    80.00                        
Tambo Memorial 16 November 2012 573 55.26    500 114.60             98.00                           100.00                    100.00                     
Far East Rand 16 November 2012 208 20.06    350 59.43                97.10                           100.00                    70.00                        
Total 1037 100.00 1200 86.42                
Site Date Assessed n=
% of Sample 
Size
% Forms with CD4 
Programme Status 
Provided (n=60)
% gender 
correctly 
captured in 
LIMS (n=10)
% CD4 
Programme 
Status correctly 
captured in LIMS 
(n=10)% Total Target
 
Figure 4.4: Study site assessment of the format and quality of the laboratory pre-ART register 
 
In the next section of the pre-ART questionnaire the study sites were requested to 
assess whether the pre-ART laboratory register: - 
 Made it easier to track patient to reduce loss to follow-up? 
 Made it easier to ensure that the paper-based records are complete? 
 Made it easier to report on the DHIS? 
 Made it easier to manage the flow to patient being staged in your facility? 
 Made it easier to follow-up patients that have not returned to the health 
facility after a CD4 test? 
 
This section also utilised a five point scale to rate each question (great assistance, 
good assistance, partial assistance, only limited assistance and no assistance at all). 
The scale was also allocated a numerical score (1-5). For each of the questions 
assessed in this section, the study sites scored between four and five again (great 
assistance and good assistance) (Figure 4.5).  
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Figure 4.5: Study site assessment of the usefulness of the laboratory pre-ART register 
 
4.3 Research Study results 
 
After achieving the required sample size at each study site, the study data extract was 
obtained from the CDW. The data extract specification stipulated that CD4 data was 
required for the three study sites for the study period (1 October 2012 to 31 January 
2013).The data was analysed using Microsoft Excel 2007 and Stata 11.  
 
4.3.1 Samples that met the inclusion criteria 
 
One of the inclusion criteria for the study was that CD4 samples should be submitted 
to the laboratory on the new CCMT request form (Form 4 page 96)  as identified by 
the unique barcode sequence captured on the LIMS, e.g. INT1234. Based on the 
barcode sequence, CD4 samples were categorised as “New CCMT request form” or 
“Other forms”. The category “New CCMT request form” was allocated when the 
barcode sequence contained “INT” for a CD4 result. An additional criteria was that 
CD4 samples for the study should be from the adult population (>= 18 years). The 
patient ages captured on the LIMS were categorised as <18 years, >=18 years and 
unknown age (where no age was captured).    
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In the data extract provided by the CDW, 4513 CD4 samples were received of which 
1266 (22.5%) were received on the new CCMT request form. The CDW data extract 
specification was designed to extract data for the study sites through the use of their 
LIMS location codes, e.g. BOK for Tambo Memorial. There were 76 samples 
requested on the new CCMT request form, where the patient ages did not meet the 
study inclusion criteria. The data set analysed for the study included 1190 eligible CD4 
results with programme status information (Table 4.9). 
 
Table 4.9: CD4 data that met the age and request form usage study eligibility criteria 
 
 
One of the criteria for the study was that the CD4 data generated by the study would 
include CD4 testing requested for pre-ART screening and routine ART monitoring. 
Therefore, at each study site, specific wards were utilised to ensure that the new 
CCMT request form were used at the wellness clinics (ART site) as well as HCT, 
antenatal and medical wards (pre-ART testing). Based on the LIMS location and ward 
codes, wards were categorised as ART ward and Pre-ART wards. 
 
For the study data, 35% (n=419) of the samples were received from Pre-ART wards 
at the three study sites, whereas 65% (771) were collected from ART wards (Table 
4.10). At each study site there was a single ART ward, but multiple non-ART wards. 
This confirms that the new CCMT request form (Form 4 page 96) was correctly 
deployed for the study.  
 
Table 4.10: CD4 data that met the ward type study eligibility criteria 
 
 
 
Request Form <=18 Unknown >=18 Total % Total
New CCMT request form 76 2 1188 1266 22.5
Other Form 996 46 3325 4367 77.5
Grand Total 1072 48 4513 5633 100
# eligible forms 1190
Ward type n= % Total
Pre-ART Ward 419 35                           
ART ward 771 65                           
Total 1190 100
4.3.2 Characteristics of study data 
 
The characteristics of the research study data described included the number of CD4 
samples submitted by each study site, a gender and age distribution as well as CD4 
result range distribution. 
 
The three study sites requested CD4 samples for the study from 1 October 2012 to 31 
January 2013 using the new CCMT request form (Form 4 page 96) as noted in table 
4.11. For the study, 1190 samples were received, with 47% (n=557) received from 
Tambo Memorial study site, 32% (n=378) from the Tembisa study site and 21% 
(n=255) from the Far East Rand site (Table 4.11). Therefore the study achieved 99% 
of the target study sample size. 
 
Table 4.11: Study sites data uptake 
 
 
The patient’s gender was provided on the new CCMT request form by health care 
workers and captured on the LIMS at the laboratory. At each follow-up visit, the capture 
of gender on the LIMS for the 10 randomly selected request forms was 100%. This is 
consistent with the gender data collected for the study. Only 2 CD4 results did not 
have a gender captured in the LIMS (0.17%). For the study a valid gender was 
captured in the LIMS in 99.8% of all CD4 samples (Table 4.12).  
 
Of the 1190 gender values captured on the LIMS, 686 were from female patients (58%) 
compared to 502 for males (42%).  
 
Table 4.12: Study gender distribution 
 
Health Facility n= % Total
FAR EAST RAND HOSPITAL 255 21           
TAMBO MEMORIAL HOSPITAL 557 47           
TEMBISA HOSPITAL 378 32           
Total 1190 100        
Gender n= % Total
Female 686 57.65     
Male 502 42.18     
Other 2 0             
Total 1190 100        
The age data collected indicates that the majority of patients where between the ages 
of 30 and 44 (59%).  Only 13.9% of patients were between the ages of 18 and 29, 
whereas 26.9% of patients were older than 45 years (Table 4.13).  
 
Table 4.13: Study age distribution 
 
 
The CD4 absolute count data was extracted and categorised into various result ranges 
to enable the analysis of the percentage of samples with a CD4 value below 50, 100, 
200 and 350 cells/µl. For the study, the data analysis revealed that 11% (n=128) of 
the CD4 results were less than or equal to 50 cells/µl, 19% were below 100 cells/µl, 
36% were below 200 cells/µl and 60% were below 350 cells/µl (Table 4.14). The 
remaining 40% of CD4 results were greater than 350 cells/µl.  
 
Table 4.14: CD4 test range distribution 
 
 
4.3.3 CCMT programme status data 
 
For the study, the programme status captured on the LIMS was analysed. Where the 
programme status provided was not appropriate, e.g. NVP (nevirapine), the data was 
categorised as “Programme status not relevant to study”. Where the data capturer had 
Age Category n= % Total
18-24 57 4.8         
25-29 109 9.2         
30-34 227 19.1       
35-39 266 22.4       
40-44 209 17.6       
45-49 123 10.3       
>49 197 16.6       
Unknown 2 0.2         
Total 1190 100        
CD4 Category n= % Total
<=50 128 11           
51-100 99 8             
101-200 198 17           
201-350 286 24           
>350 479 40           
Total 1190 100        
captured the LIMS coded comment “NDS” (No Data Supplied) on the LIMS to reflect 
that the health care worker had not provided a programme status, the data was 
categorised as “No details provided by HCW”. Where no CCMT programme status 
data was captured on the LIMS, the data was categorised as “No data 
captured/provided”. The valid CCMT programme status options included “First ever 
CD4”, “CD4 taken previously, not yet in ART care” and “In ART care”. 
 
To analyse the provision and capture of the programme status for the study, the 
percentage of samples received with a valid programme status was assessed. For the 
study, 84.4% (n=1004) of the CD4 samples had a valid programme status noted. This 
is a significant improvement from 27.56% reported for the pre-study baseline analysis 
(using Form 3 Page 95). The Tambo Memorial study site reported the highest rate of 
valid programme status provision on the LIMS (89%).  
 
Only 14.2% (n=165) of the CD4 samples for the study did not have a programme 
status captured on the LIMS (unable to assess whether a programme status had been 
provided by the health care worker (Table 4.15).  
 
A small number of samples of (n=17 1.43%) were categorised as “Programme status 
not relevant to the study”, e.g. NVP (nevirapine). For these samples the incorrect 
information was captured on the request form, i.e. drug status. However, this does not 
imply that these patients were not in ART or wellness care.  
 
There were only 4 (0.34%) CD4 results where the programme status captured on the 
LIMS indicated that the health care worker had not provided a programme status, e.g. 
NDS (No Data Supplied).  
 
Table 4.15: CCMT programme status distribution for CD4 results 
  
CCMT Programme Status n= % Total
First ever CD4 309 25.97     
CD4 taken previously, not yet in ART care 74 6.22       
In ART care (please mark drugs) 621 52.18     
No data captured/provided 165 13.87     
No details provided by HCW 4 0.34       
Programme status not relevant to study 17 1.43       
Total 1190 100.00  
The percentage of Pre-ART and ART programme status captured on the LIMS for 
each study site was assessed. To calculate these percentages only the valid 
programme status (highlighted in yellow) were included (n=1004). For the study 38% 
(n=383) of the CD4 samples with a valid programme status were received with a pre-
ART programme status category, compared to 52% (n=621) for an ART programme 
status category (Table 4.16). For the Tambo Memorial and Tembisa study sites the 
proportion of CD4 samples received with a pre-ART or ART programme status were 
similar, at the Far East Rand study site samples were received mainly with an ART 
programme status (92%). 
 
Table 4.16: CCMT programme status distribution for CD4 results at the three study sites 
 
 
The ward codes captured on the LIMS for each study site were categorised as “ART 
ward” for wards that provided ART services or a “Non-ART” ward where the ward was 
not offering ART. The Far East Rand study site submitted only 5% (n=13) of their CD4 
samples for the study from non-ART wards, compared to 38% (n=214) and 51% 
(n=192) for the Tambo Memorial and Tembisa study sites respectively (Table 4.17).  
 
Table 4.17: New CCMT request form usage for the ward type at the three study sites 
 
 
One of the objectives of this study was to report the proportion of patients about to 
start ART with a CD4 count below 50 cells/µl. The CCMT programme status categories 
Programme 
Status Category
CCMT PROGRAMME Status
FAR EAST RAND 
HOSPITAL
TAMBO MEMORIAL 
HOSPITAL
TEMBISA 
HOSPITAL
 Total
% 
Total
First ever CD4 13 162 134 309 26
CD4 taken previously, not yet in ART care 3 44 27 74 6
ART In ART care 192 288 141 621 52
No data captured/provided 46 47 72 165 14
No details provided by HCW 1 3 4 0.34  
Programme status not relevant to study 16 1 17 1
255 557 378 1190 100
21 47 32 100
82 89 80 84
8 42 53 38
92 58 47 62
pre-ART
Other
 Total
% Total
% Valid CCMT Programme Status
% Pre-ART Programme Status (of the valid CCMT 
Programme Status options)
% ART Programme Status (of the valid CCMT Programme 
Status options)
Ward Type
FAR EAST RAND 
HOSPITAL
TAMBO MEMORIAL 
HOSPITAL
TEMBISA 
HOSPITAL  Total % Total
ART ward 242 343 186 771 65
Non-ART ward 13 214 192 419 35
 Total 255 557 378 1190 100
% Non-ART ward 5 38 51 35
for this study objective are the “First ever CD4” and “CD4 taken previously, not yet in 
ART care” results. The CD4 results for the study were categorised into two test ranges 
(<=50 and >50 cells/µl). For this study, 11% of all CD4 samples tested were below 50 
cells/µl. For the pre-ART CCMT programme status category, however this increased 
to 22% (Table 4.18). The percentage of CD4 samples with counts below 50 cells/µl 
was 24% for “First ever CD4” and 14% for “CD4 taken previously, not yet in ART care” 
programme status. Therefore one third of the patients with a CD4 count below 50 
cells/µl were not yet in ART care. 
 
Table 4.18: Proportion of patients about to start ART with a CD4 count below 50 cells/µl 
 
 
The current South African ART guidelines define the eligibility criterion to start ART at 
a CD4 count of 350 cells/µl (NDOH 2010:8). The study data pre-ART programme 
status was used to assess the number of patients that would be eligible for ART. For 
the study, 74% (n=282) of the patients with a pre-ART CCMT programme status were 
eligible for ART (current guidelines). This increased to 79% for CD4 samples with a 
“First ever CD4”programme status (current guidelines) (Table 4.19). The new WHO 
guidelines released in 2013 recommend that patients with CD4 count between 350 
and 500 cells/µl should also be placed on ART irrespective of their WHO clinical stage 
(WHO 2013b:2). If these guidelines were to be adopted in South Africa, based on the 
study results, 87% (n=334) of these pre-ART patients would eligible for ART.  
 
 
 
 
 
<=50 >50 Total % <=50
First ever CD4 75 234 309 24
CD4 taken previously, not yet in ART care 10 64 74 14
Total 85 298 383 22
ART In ART care (please mark drugs) 11 610 621 2
No data captured/provided 28 137 165 17
No details provided by HCW 1 3 4 25
Programme status not relevant to study 3 14 17 18
128 1062 1190 11
11 89 100
pre-ART
Other
 Total
% Total
CCMT Programme Status
Table 4.19: Proportion of patients with a pre-ART CCMT Programme Status that are eligible for 
ART 
 
 
The study CD4 mean was 323 cells/µl with a median of 288 cells/µl. For CD4 samples 
with a programme status of “First ever CD4” the median CD4 was 150 cells/µl, 
compared to a median CD4 of 346 cells/µl for samples with an “In ART” programme 
status (Table 4.20).  
 
Table 4.20: CD4 Count mean and median for CCMT Programme Status codes 
CCMT Programme Status n= Mean Median CD4 %Total 
First ever CD4 309     220  150  
CD4 taken previously, not yet in ART care 74     327  328 32 
In ART care (please mark drugs) 621     379  346 52 
No data captured/provided 165     309  274  
No details provided by HCW 4 261 267  
Not a CCMT Programme Status 17     293  267  
Total 1190     323  288  
 
4.4 Conclusion 
 
The research findings have clearly described the number of CD4 samples for the 
baseline and study data at the three study sites as well as the median CD4. 
Additionally, the findings of the follow-up site visits identified some of the challenges 
encountered as well as the level of compliance for data collection and capture.  
 
Pre-ART CCMT Programme Status <=350 >350 <=500 >500 Total
% CD4 samples 
<= 350 cells/ul
% CD4 samples 
<= 500 cells/ul
First ever CD4 243 33 33 309        79% 89%
CD4 taken previously, not yet in 
ART care
39 19 16 74          53% 78%
Total 282 52 49 383        74% 87%
% Total 74% 14% 13% 100%
CHAPTER 5: CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 Introduction 
 
This chapter critically evaluates the results of the study and provides the conclusions 
for the findings as well as recommendations. The study results are discussed with 
available literature to relate findings to previous studies. This chapter assesses 
whether the intervention of the new CCMT request form provides comprehensive and 
accurate CCMT programme status data compared to the findings for the baseline 
study. Limitations inherent in the study will also be discussed in this chapter.   
 
5.2 Research design and method 
 
This was a quantitative research study that employed the methodological research 
design (empirical). Although one of the limitations of this study design is the 
applicability of results to other contexts, it is well suited for piloting the implementation 
of a new data collection tool. 
 
The study population consisted of patients attending the Tembisa, Tambo Memorial 
and Far East Rand study sites in the Ekurhuleni district for HIV care. The health care 
workers at the study sites used the new CCMT request form when patients required 
CD4 testing during the study period.  
 
Data was collected using the completed new CCMT request form and the LIMS at the 
study sites. Once the data was captured in the LIMS, it was replicated to the Corporate 
Data Warehouse and extracted without patient identifiers. The data was analysed to 
ensure that all CD4 results met the inclusion criteria for the study. Data analyses was 
done with Microsoft Excel and Stata 11, and included calculating the median CD4 for 
pre-ART and ART CCMT programme status categories, the percentage of CD4 
samples in the pre-ART and ART programme status categories and the proportion of 
patients about to start ART with a CD4 count below 50, 350 and 500. 
 
5.3 Summary and interpretation of research findings 
 
5.3.1 The laboratory based CCMT Programme Status reporting system 
 
The study was designed to address the following key issues:  
 Establishing the impact of use of the tick box system to capture HIV ART 
programmatic status. 
 Establishing the usefulness of the laboratory pre-ART register (assessed with a 
questionnaire) 
 Establishing the median CD4 for ‘pre-ART’ and ‘ART CCMT’ programme status 
groups, at each of the health facilities, as an indirect indicator of overall patient 
programmatic immune status. 
 Establishing the percentage of patients in the pre-ART and ART programme status 
categories as a percentage of total CD4 samples received, to define eligibility for 
treatment. 
 Establishing the proportion of patients eligible to start ART with a CD4 count below 
50 (specifically included for the study as the national M&E framework for the NSP 
2007-2011, as an indicator to measure the proportion of patients with a CD4 count 
<= 50 on start (NDOH 2009)). 
 Establishing the number of patients that were eligible for ART, but not yet enrolled 
onto treatment programmes. 
 Contextualising the outcomes in light of the new NDOH guidelines for treatment. 
 
In the baseline data analysis study a total of 3168 CD4 samples were requested 
between June and July 2012, of which 3103 (98%) were requested on the existing 
CCMT request form. However, only 873 (27.56%) had a CCMT programme status 
captured on the LIMS.  
 
For this study, 1266 CD4 samples from the three study sites were received on the new 
CCMT request form between October 2012 and January 2013.  Six percent (6%, n=76) 
of samples were excluded as they did not fulfil the study eligibility criteria.  The study 
reached 99% of the target sample size (n=1190, original macorr calculation of 1200). 
The study was conducted with minimal interruption to routine health care services at 
the three study sites with health care workers only required to place an extra tick when 
requesting a CD4 test on the new CCMT request form. During the follow-up visits in 
weeks 2, 4 and 7 of the study, the level of data provision by health care workers was 
high (well over 80% for all three visits). At the laboratory level, the data capture rate 
was poor only at one study site during week two and four follow-up visits, but improved 
with additional training. By the time the study data was extracted, all three laboratory 
sites had captured the CCMT programme status for 80% or more of the CD4 samples 
requested for the study.  
 
The aim of the study was to develop a laboratory based CCMT Programme Status 
reporting system specifically to evaluate HIV patient programme ART status linked to 
the request for CD4 testing in the Ekurhuleni Health District. The study demonstrated 
that this reporting system was easily implemented into routine healthcare services 
delivery. Data was collected as part of the process of requesting a CD4 test by the 
health care workers and subsequently captured by the data capturer as part of 
registering the CD4 test on the LIMS. Lastly, the data transferred across to the NHLS 
Central Warehouse Database for data analysis.  
 
There are a number of factors that facilitated successful collection of the data for the 
study. The LIMS test methods had already been designed to collect a specific set of 
information such as the CD4 results (CDARV) or in the case of the new CCMT form, 
the newly designated CCMT programme status (ARVID) linked to the request for CD4. 
Typically, within each test method, parameters are created to capture a specific data 
variable, e.g. CD4 absolute count, with drop down lists for categorical data such as 
the CCMT programme status. For continuous data, like entry of CD4 results, the LIMS 
provides the functionality to limit entries to valid number formats and ranges and to 
perform delta checking. These features make it easy for the data capturers to collect 
the information on the LIMS without transcription or other errors, different from a paper 
based system where data is manually entered into an electronic data system, often 
days later and frequently with transcription and other errors occurring.  
 
The findings of the study demonstrate a dramatic improvement in the provision and 
capture of the CCMT programme status from 28% in the baseline data extract to 84% 
for the study. This success can be attributed to interventions initiated through the 
study, including the design of the new CCMT request form (Form 4 page 96), simple 
tick box choices to indicate programme status, the provision of on-site training, 
standardisation of data captured on the LIMS and data review during the follow-up 
visits.  
 
The percentage of CD4 samples with a pre-ART and ART programme status was 
assessed by using the CCMT programme status codes captured in the LIMS. Overall 
for this study 62% (n=621) of the CD4 samples had an ART CCMT programme status 
category, compared to 38% for pre-ART CCMT programme status category.  This 
indicates that the CCMT M&E system can be used to assess the proportions of CD4 
samples requested for routine ART monitoring as well as pre-ART CD4 testing 
following HCT. It therefore has the potential to report on how many CD4 samples were 
received following HCT as an indirect measure of HCT linkage to care. It is of concern 
that almost a third of the patients had a CD4 count but was not yet enrolled on ART.  
The study sites were satisfied with the quality of the data reported by the laboratory 
pre-ART register. They also rated the format of the register through a self-administered 
questionnaire either excellent or very good. The study sites indicated that the 
laboratory pre-ART register was useful to follow-up pre-ART patients as well as 
improve their reporting to the DHIS.  These findings demonstrate the ability of the 
study to collect the data required to generate a pre-ART register. Although the 
laboratory based pre-ART register present challenges, it has the potential to improve 
how pre-ART services are offered in South Africa by providing a list of patients that 
need to followed-up and initiated on ART.  
 
There were a number of interventions required to develop a laboratory based CCMT 
Programme Status reporting system in the Ekurhuleni Health District. The first 
intervention was the redesign of the new CCMT request form (Form 4 page 96). One 
of the key changes was to link the process of requesting a CD4 test using the “two-
tick” principle which links the request of the CD4 test with the CCMT programme status 
options, prompting health care workers to add the required additional information. By 
associating the two elements in close proximity it was assumed that the CCMT 
programme status information would be provided more often, as the health care 
worker would not have to go and look for the CCMT data element elsewhere on the 
new CCMT request form. Secondly the CCMT programme status options, provided on 
the request form, were limited to just three options that specifically related to CD4 
testing. Finally, on the new CCMT request form the CD4, HIV viral load and EID tests 
were placed first as they the most frequently requested tests. These key changes all 
worked together to improve the comprehensiveness and quality of data collected for 
this study.   
 
Training proved to be an important component of the success of these parameter 
changes and ensuring the capture of relevant programme status information. Training 
was provided to health care workers using a standardised presentation and training 
guide. During the health care worker training the “two-tick” system was emphasised 
and health care workers were required to complete the new CCMT request form. A 
more detailed training was provided for data capturers. The quality of training 
interventions was assessed during the follow-up visits where the provision and capture 
of the CCMT programme status on the new CCMT request form (Form 4 page 96) and 
LIMS respectively, was assessed. Only the Far East Rand study site required some 
follow-up training and support. This demonstrates that the combination of the training 
and follow-up visits are key to the integration of the CCMT programme status M&E 
system in other health districts. It also confirms that when data is being reviewed on a 
regular basis, the quality of the study data improved. Long term strategies and 
resources, however, need careful review and planning to ensure training programmes 
and support for users is sustained. 
 
To implement the laboratory based CCMT Programme Status reporting system 
nationally would be a large undertaking and would need to be sustainable in the long 
term. For the study, most of the interventions were planned and executed by a small 
team led by the researcher. For a national rollout, a more sustainable implementation 
model would be required i.e. dedicated roll-out task team to do training and follow up 
visits.  
 
Long term planning can be achieved through the use of the practical, robust 
implementation and sustainability model (PRISM) developed in 2008, as a tool for 
researchers to translate their research into practice (Feldstein and Glasgow 
2008:228). This model requires the researcher to review the interventions proposed, 
the recipients of the intervention, the external environment, the implementation and 
sustainability infrastructure and aspects related to the adoption, implementation and 
maintenance of the intervention (Feldstein et al 2008:230). For the sustainability of the 
implementation of the laboratory-based CCMT Programme Status reporting system, 
recommendations for organisational and patient perspectives for the intervention are 
discussed. Additionally the proposed intervention, sustainability infrastructure, 
implementation and maintenance are also considered. Further details about the 
proposed PRISM model to translate this research into practice are provided in 
Annexure L (Page 159).   
 
A national mandate and approvals are required to implement the laboratory based 
CCMT Programme Status reporting system (NDOH and NHLS) and take it to the next 
level, co-ordinating the process through the NDOH laboratory co-ordinators quarterly 
meetings. Laboratory co-ordinators are appointed within the NDOH to manage their 
relationship with the NHLS at a national, provincial and district level. These co-
ordinators are able to discuss the proposed intervention within the NDOH 
organisational structures and provide input to the national laboratory co-ordinators 
quarterly meetings. The NDOH would be required to approve the intervention and 
distribute an official letter to the provincial Heads of Departments (HOD’s). Within the 
NHLS, the Chief Operating Officer (CEO) would issue an internal memorandum to 
implement the intervention following extensive consultation with regional and business 
managers. There would be minimal impact on patients (patient perspective) by the 
intervention as the only change would be the use of a different request form by the 
health care worker. There is no perceived negative impact anticipated for patients.  
 
The study also revealed that there are many organisational aspects that had to be 
dealt with during the course of the study. Some of the organisational aspects related 
to the NHLS laboratory services while others related to the three study sites.  
 
For this study, it was vital that the same LIMS was used throughout the study, as this 
enabled the collection of the CCMT programme status codes in a consistent format. A 
change to the LIMS would require retraining data capturers, configuring new test 
methods and parameters as well as data differently through the Corporate Data 
Warehouse.  
The study also revealed the presence of good laboratory management facilitated the 
provision of the CCMT programme status on the LIMS. The follow-up visits identified 
that the Tambo Memorial and Tembisa data capturers were performing better than 
their counterparts at Far East Rand. During the study period, the Far East Rand 
laboratory manager was on maternity leave.  
 
The availability of experienced data analysts at the CDW will ensure the long-term 
success and integrity of the data generated. 
 
The study also revealed that wards that were allocated to use the new CCMT request 
form at each study site did not materialise. At the Far East Rand study site, CD4 
samples were predominantly received from the ART ward. These findings highlights 
an institutional challenge that could be addressed with training initiatives for health 
facility managers. 
 
The study also revealed an additional organisational aspect the study had to contend 
with. This related to the decentralisation of ART services to the primary health care 
(PHC) facilities surrounding the three study studies using a nursing staff to initiate 
patients on ART (NIM-ART). The health care workers at the study sites had indicated 
that nurses in the PHC clinics had been NIM-ART trained and were planning to start 
initiating patient on ART. As the study commenced the step down of stable patients 
on ART to PHC clinics had started. According to Colvin, Fairall, Lewin, Georgeu, 
Zwarenstein, Bachmann, Uebel and Bateman (2010:210) the policy decision by the 
South African government to expand access to HIV care rapidly and ensure that all 
health facilities to provide ART is a dramatic and welcome change for the situation 
when only a few accredited health facilities were offering ART. Due to implementation 
of NIM-ART it appeared as though patients preferred to attend a closer health facility 
instead of coming to one of the study sites.  
 
A median CD4 result of 150 cells/µl, noted in the group of patients receiving their ‘first 
ever CD4 count’, reveals a largely unwell group requiring an urgent treatment 
intervention. Lamb et al (2012:1) reported data for adults enrolled in HIV care between 
January 2005 and December 2010 from 190 health facilities in Kenya, Mozambique, 
Rwanda and Tanzania. This study found that patients initiating ART had a median 
CD4 of 144 cells/µl, similar to that noted in the current reported study, whilst patients 
already enrolled into HIV care were noted to have a median level of 259 cells/µl. These 
results are not dissimilar to the “First ever CD4” median of 150 cells/µl reported here. 
However the median CD4 count of the “in ART care” group noted in this study is 90 
cells/µl higher, at 349 CD4 cells/µl, indicating patients are responding more actively to 
treatment.  
 
The finding of a median CD4 of 150 cells/µl for patients with a “First ever CD4” 
programme status for the study indicates that these patients should, preferably be fast-
tracked on ART. Low presentation CD4 counts increases the likelihood of disease 
progression to AIDS or death and opportunistic infection if patients are not initiated 
onto ART (WHO 2007:16)  According to the WHO immunological classification for 
established HIV infection (WHO 2007:17), this group has twice the risk of death or 
virological failure. In this regard, a local randomised controlled trial (RCT) was 
conducted in Johannesburg and Cape Town, where ART naïve HIV positive patients 
(n=812) were followed up for a minimum of 96 weeks (Fox, Sanne, Conradie, 
Zeinecker, Orrell, Ive, Rassool, Dehlinger, van der Hirst, McIntyre and Wood 
2010:2042). This study reported that patients with a CD4 count below 200 cells/µl had 
roughly twice the risk of death or virological failure than those patient’s that initiated 
on ART at CD4 counts above 200 cells/µl (Fox et al 2010:2042). For the present study, 
patients with a “First ever CD4” programme status are presenting with severe HIV-
associated immunodeficiency according to the WHO immunological classification for 
established HIV infection (WHO 2007:17) and may additionally, also be presenting 
with opportunistic infections and other HIV related conditions (WHO 2007:16) 
complicating presentation and contributing to the low median CD4 reported. 
 
One of the additional study objectives was to assess the proportion of patients about 
to start ART with a CD4 count below 50 cells/µl. The pre-ART CCMT programme 
status category was used to identify CD4 testing performed for patients about to start 
ART. The CD4 results were then categorised into two test ranges, <=50 cells/µl and 
>50 cells/µl.  Overall 11% of the study samples (ART and pre-ART) had a CD4 count 
below 50 cells/µl. The proportion of pre-ART samples with a CD4 count below 50 
cells/µl was 22 percent (n=85). This increased to 24% (n=75) for CD4 samples with 
“First ever CD4” CCMT programme status, and 14% (n=10) for “CD4 taken previously, 
not yet in ART care”.  
 
Mechanisms to motivate patients to present for care earlier are required considering 
the low median CD4 count reported here. One such initiative of the NDOH, is the 
introduction of the PHC re-engineering strategy that will include the creation of ward-
based PHC outreach teams that provide health care service for a defined municipal 
ward(NDOH 2011f:2). These teams will include a professional nurse, environmental 
health and health promotion practitioners as well as six community health care workers 
(CHW) (Pillay and Barron 2011:3). The main function of the ward-based PHC outreach 
teams is to promote good health and prevent ill-health (Pillay et al 2011:3). 
 
In addition to making it easier for patients to access health care services with the ward-
based outreach teams, it is also critical to understand some of the other reasons why 
patients are presenting late in order to provide a service that will address this problem. 
In another South African study, patients presenting for voluntary HIV counselling and 
testing (VCT) were studied at four outpatient clinics in Durban (Drain, Losina, Parker, 
Giddy, Ross, Katz, Coleman, Bogart, Freedberg, Walensky and Bassett 2013:3). In 
this study, late presentation was defined as a CD4 count below 100 cells/µl (Drain et 
al 2013:1). Some of the reasons for late presentation included living far from a health 
facility (incurring unaffordable transport costs), paying for basic necessities and 
foregoing healthcare, working away from home (migratory), long waiting times at the 
health facilities and perceptions of barriers to health service delivery (Drain et al 
2013:7).  
 
Late presentation of patients can lead to high secondary and tertiary health facility 
costs related to hospital presentation. Although there is no local costing data 
published, a Canadian study was conducted in 2004 to compare the costs of medical 
care in the year following HIV diagnosis for both early and late presenters (late 
presenters <=200 cells/µl) (Krentz and Gill 2012:93). This study reported that direct 
medical costs in the year following HIV diagnosis were more than 200% higher for 
patients who presented late, and that these costs were incurred by HIV-related 
hospital care and initiation on ART (Krentz and Gill 2012:93). In a South African 
context due to high HIV prevalence, population demographics and other factors, it is 
clear that late presentation can incur unnecessary costs for the public health care 
system, as these patients additionally present with HIV related opportunistic such as 
Tuberculosis and cryptococcosis, prior to commencing ART. Early diagnosis and 
enrolment onto treatment programmes will improve overall patient immune status and 
decrease onset/ occurrence of related opportunistic infections. The planned primary 
health care outreach teams will, it is hoped in future, make it possible to identify these 
patients before their CD4 counts drop below 100 - 200 cells/µl level. Such outreach 
programmes could potentially reduce the cost on the public health system while 
improving the outcomes of these patients. 
 
In April 2013, the NDOH released the new ART clinical guidelines including changing 
the eligibility criteria for ART, based on a CD4 count, from 200 cells/µl to 350 cells/µl 
for all HIV adult patients. (NDOH 2013:6). This study reports that patients with a 
programme status “CD4 taken previously, not yet in ART care“ had a median CD4 
count of 328 cells/µl. This new guideline change would thus enable these patients 
enrolled onto wellness programmes with a CD4 count between 201 and 350 cells/µl 
to access ART. Of the patients presenting with a “First ever CD4” programme status, 
59% (193) would have been eligible for ART with the 2010 ART guidelines whilst 93% 
(n=243) had a CD4 count below 350 cells/µl and would be eligible for ART (20% 
increase). 
 
Results from this study reveal that there are significant numbers of patients in this 
group who are currently not eligible for ART but who may be enrolled in the HIV 
wellness programme at their local health facility. Here, approximately 53% of patients 
(n=39) had a CD4 count below 350 cells/µl will qualify for treatment and 78% (n=58) 
will qualify if the guideline for treatment is extended to include all patients with a CD4 
count below 500 cells/µl (WHO 2013b:29).In 2013, the World Health Organisation 
(WHO) released its consolidated ART guidelines (WHO 2013b:29). These guidelines 
state that as a priority, ART should be initiated in all patients with severe or advanced 
HIV clinical disease (WHO clinical stage 3 or 4) or a CD4 count  below 350 cells/µl 
(WHO 2013b:29). Additionally patients with a CD4 count between 351 and 500 cells/µl, 
currently being referred to the wellness programme in South Africa should be initiated 
on ART (WHO 2013b:29). The change to the ART guidelines to make ART available 
at a CD4 count <= 500 cells/µl would increase the percentage of patients presenting 
for first ever CD4 testing from 79% (current South African ART guidelines) to 89% 
(WHO ART guidelines). The universal test and treat strategy would only add an 
additional 11% of patients with a “First ever CD4” programme status. It would therefore 
be more cost effective to change the South African ART guidelines in line with WHO 
recommendations. 
 
Patients in this group may not necessarily be enrolled for wellness evaluation though 
and may be lost to follow-up. In a local study, of 356 patients enrolled in the wellness 
programme at the Themba Lethu clinic in Johannesburg, 69% (n=244) of patients 
enrolled in pre-ART care did not return for their ﬁrst medical visit within one year of 
enrolment (Larson et al 2010:45). Furthermore, 21% (n=75) of these patients had a 
CD4 count below 350 cells/µl and were eligible for ART (Larson et al 2010:45).  
 
In another local study HIV-infected adults not yet eligible for ART, with CD4 cell count 
greater than 200 cells/µl were followed up to assess whether they were retained in 
wellness care (Lessells, Mutevedzi, Cooke, and Newell 2011:79). For the study 
retention was defined as having a repeat CD4 count within 13 months of the earlier 
CD4 count (at which the patients were not eligible for ART) (Lessells et al 
2011:79).The study reported the retention rates by the initial CD4 test range. For 
patients with an initial CD4 count between 201 and 350 cells/µl, the retention was 
51.7% (Lessells et al 2011:79). The retention rate however dropped to 43.2% for CD4 
counts between 351 and 500 cells/µl (Lessells et al 2011:79). Patients with CD4 
counts greater than 500 cells/µl had the lowest retention rate at 34.9% (Lessells et al 
2011:79). This study confirmed that late presentation affects the retention rate on ART, 
therefore it is vital that these patients are identified earlier. 
 
In this study, 47% of the patients in the wellness programme (programme status of 
“CD4 taken previously, not yet in ART care”) had a CD4 count greater than 350 cells/µl. 
Similarly, based on the results of the Larson et al study (2010:45), of the 53% of 
patients that are eligible for ART, many patients may not return to be initiated on ART. 
 
Urgent interventions are therefore required. In 101 subjects on ART, a median 
baseline CD4 of 380 cells/µl was reported. Recent WHO guidelines suggest that it 
would be advantageous to increase the CD4 count threshold for ART initiation to 500 
cells/µl. This study suggests that a test and treat strategy may be worthwhile bearing 
in mind the overall median count of 348 cells/µl, which falls within the current guideline 
range for ART eligibility. The latter strategy, known as Universal Test and Treat 
strategy, involves testing the entire population for HIV once a year and then treating 
immediately all HIV positive patients on ART (Dodds, Garnett and Hallett 2010:729). 
The hypothesis for the Dodds et al study (2010:729) is that this approach has the 
potential to eliminate the HIV epidemic and reduce ART costs in the long-term. Their 
study investigated the impact of test and treat interventions under various assumptions 
about the HIV epidemic using a deterministic mathematical model (Dodds et al 
2010:730).The median CD4 values reported here show that the test and treat 
intervention could substantially increase numbers of patients on treatment, and hence 
reduce HIV transmission. The impact of the intervention, however, depends on the 
epidemiological context. Full coverage is however crucial in order not to increase long-
term ART costs (Dodds et al 2010:730). Careful assessment is necessary before 
implementing such a strategy in a country like South Africa. 
 
This study reported that patients with a programme status of “In ART care“ have a 
median CD4 count of 348 cells/µl. Although the period of enrolment is not known for 
the patients in this study, the median value is not dissimilar to that reported by Bosch, 
Wang, Vaida, Lederman and Albrecht (2006:433). Patients reported response to 
treatment has been generally slow in local studies. In HIV-sero-positive patients 
recruited for the CIPRA “Safeguard the Household” project, (Glencross, Janossy, 
Coetzee, Lawrie, Scott, Sanne, McIntyre, and Stevens (2008:133), the absolute CD4 
count following the ﬁrst 4 weeks of ART increased from 186 cells/µl at baseline to 267 
cells/µl (Glencross et al 2008:137). Additional two phases in the increase of the CD4 
count following ART was noted. Following 4 weeks of ART the CD4 count gained 
between 50 and 120 cells/µl (Glencross et al 2008:138). However, in the second phase 
an almost imperceptive slow increase of CD4 count was reported (Glencross et al 
2008:138). The data collected for the study using the programme status is unable to 
differentiate the length of time on ART, hence it becomes difficult to directly compare 
the median CD4 of 348 cells/µl obtained for the study to the published South African 
CIPRA data (Glencross et al 2008:137).  
 
5.3.2 Key components for CCMT Programme Status M&E system 
 
To develop a functional CCMT programme status M&E system within the context of a 
broader health data systems is a very important consideration. The output of the 
CCMT programme status M&E system must fit within broader NDOH M&E reporting 
systems. The UNAIDS describes a programme logic model which can be used to 
assess the data generated by the study against six key concepts and frameworks that 
form the foundation of a M&E system for HIV services (UNAIDS 2010:48). The 
UNAIDS programme logic module has number of requirements for an M&E system:- 
 contains a program logic model where the main elements of the intervention 
including the assumptions made, problem statement, inputs, activities, outputs, 
outcomes and impacts are described (UNAIDS 2010:48). 
 The elements should all work together to reach the program’s goal (UNAIDS 
2010:49).  
 Data should be collected with the intention of being used. This includes defining 
the inputs and activities that are required to generate the M&E outputs 
(UNAIDS 2010:49) 
 The M&E system should adopt a systems perspective, whereby all the M&E 
system components need to be present and work to an acceptable standard 
for the M&E system to function effectively (UNAIDS 2010:53). 
 
  
 
Figure 5.1: Programme Logic Model for the laboratory based CCMT Programme Status 
reporting system 
 
5.3.3 Limitations of the study 
There were a number of limitations identified during the course of the study were as 
follows:- 
 
ASSUMPTIONS
CD4 testing is performed with the NHLS using the LIMS to programme status data
A national request form includes the CCMT programme status options for HIV related testing
All M&E data is reported to the NDoH via the DHIS
The laboratory based CCMT Programme Status reporting system becomes an additional system 
within the national M&E systems employed by the NDoH (described in the conceptual framework)
NHLS and NDoH approve the implementation of the laboratory based CCMT Programme Status 
reporting system
PROBLEM STATEMENT
The absence of a national electronic HIV monitoring and evaluation system to 
monitor CD4 patient data designated according to pre-ART/ HCT and ART status in 
CCMT Programme 
Develop a system to monitor the number of patients accessing the system for the 
first time for CD4 testing (pre-ART) 
ACTIVITIES
 National CCMT request forms 
printed and delivered to NHLS 
laboratories (national tender)
 NHLS laboratories manage 
the distribution of the request 
forms to health facilities
 Conduct on-site training for 
HCW and data capturers
 Use the LIMS to collect CD4 
results and programme status 
data
 Conduct follow-up visits
 Extract and analyse data
 Review data to assess M&E 
output
OUTCOMES
 GeneratIon of facility level data for the laboratory based CCMT Programme Status reporting system
 Improved monitoring of pre-ART CD4 testing, in particular how many patients are presenting late as 
well as the proportion eligible for ART.
 Potential to reduce pre-ART loss to follow-up.
IMPACTS
 Improved monitoring of patients in pre-ART care
 Alternative source of data to correlate pre-ART register data reported via the DHIS
OUTPUTS
 Generate facility based 
pre-ART register
 Generate facility based 
M&E summary report from 
the LIMS
 Health Facilities to report 
data on the DHIS
 Health facilities to use pre-
ART register to follow up 
patients that are eligible for 
ART
 M&E reports integrated into 
facility management review 
process
INPUTS
 Development of a national CCMT 
request form that utilises the “two-
tick” system
 Develop HCW and data capturer 
training materials
 Provide facility-based training
 NHLS laboratories use an LIMS for 
CD4 testing
 LIMS test methods and parameters 
designed nationally to collect the 
CCMT programme status 
information
 LIMS M&E reports developed 
 LIMS data is replicated to the CDW
 Due to limited funding and resources, the study was limited to the three out of 114 
of the busiest public health facilities in the Ekurhuleni health district public health 
facilities in this health district (Magoro 2012).The study was also conducted at three 
hospitals and could not include a mix of primary health facilities and hospitals. 
Should the study have included hospitals, community health centres and primary 
health care facilities the study would have produced results that could be 
generalised to the entire health district. Nevertheless it was considered to be a 
representative sample. 
 
The collection of the CCMT programme status was limited to collecting data for CD4 
testing and CCMT programme status data. Due to the size of the team undertaking 
the research and limited funding available it was not possible to increase number of 
study sites or the sample size.  
 
5.4 Recommendations 
 
Based on the research findings the following recommendations are suggesting for 
enhancing the monitoring and evaluation of the CCMT programme and will be 
classified as either of high, medium and low importance:- 
 The development of an NHLS standard for the design of NHLS request forms 
that will be used for the collection of data for the CCMT programme or other 
priority programmes. Based on the results from this study, it is proposed that 
the data collection tools on the priority programme test be linked to the position 
on the request form where the respective test is being requested, i.e. using a 
two-tick system. Additionally the data collected for each test should relate only 
to that test and that the options provided must be mutually exclusive (High 
priority). 
 The establishment of management reports on the TrakCare LIMS system that 
will enable laboratory managers to extract the laboratory pre-ART register and 
the summary M&E data, i.e. pre-ART and ART median CD4, proportion of pre-
ART and ART CD4 samples, the proportion of CD4 counts <= 50 cells/µl or 
other levels with pre-ART CCMT programme status. This recommendation 
would allow for decentralising the provision of data to the health facility (Medium 
priority). 
 
5.5 Concluding Remarks 
 
The data collected for the study using the newly developed CCMT request form and 
the LIMS was analysed and discussed. The results of the study demonstrate a 
dramatic improvement in the provision and capture of the CD4 CCMT programme 
status, data increasing from 28% to 84% using the new CCMT request form (56% 
improvement in data provision and capture). 
 
This marked improvement in the comprehensiveness and quality of data can be 
attributed to a few interventions in the study. A key finding of the study was that using 
the two-tick system on the new CCMT request form (Form 4 page 96) improved the 
provision of data dramatically from the baseline data analysis. Additionally by using a 
standardised LIMS across all three sites with specially designed data screens for the 
capture of the CCMT programme status data meant that it was easier to capture this 
data in streamlined manner. 
 
The positive study findings could not have been achieved without the on-site training 
offered to health care workers and laboratory data capturers. The training was 
supported by follow-up visits to ensure that local practices complied as far as possible 
to the required standard early in the study. Offering ongoing training to health care 
workers and data capturers will be crucial to embed the provision and capture of the 
CD4 CCMT programme status as part of routine health care services. 
 
The future sustainability of the study recommendations are important as the study was 
largely delivered by researcher efforts. The PRISM model was used to assist in 
providing guidelines on how to extend the research findings to national implementation 
of the laboratory based CCMT Programme Status reporting system. A comprehensive 
monitoring and evaluation control programme needs to be implemented in all 114 
health facilities as a means of ensuring value for money. This recommendation is 
consistent with similar recommendations made in the past by the WHO for Health 
Ministries in Sub-Saharan African countries such as South Africa (WHO 2008). 
 
The study also highlighted the many logistical aspects related to the study. These 
included the proposed change from one LIMS (Disa*Lab) to another (TrakCare) 
halfway through the study. The level of local supervision of health care workers and 
laboratory data capturers was also raised by the study.  
 
A similar study should be extended to a larger number of health facilities that include 
a mix of hospitals, community health centres and primary health care clinics. 
Additionally the results of this study should be reported to the NHLS/NDOH to make 
them aware of the findings and recommendations. The findings of the study should 
also be published in a peer reviewed journal so that it may guide similar approaches 
in other health districts. 
 
This study has demonstrated that it is possible and feasible to develop a laboratory 
based CCMT Programme Status reporting system using the new CCMT request form 
in the Ekurhuleni health district. 
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Data Extract One: Baseline CCMT programme status data 
 
 
 
 
 
 
  
 
  
 
 
  
 
 
  
 
 
 
 
 
Data Extract One: Communication with data analyst 
 
  
Data Extract Two: Study data 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Data Extract Two: Communication with data analyst 
 
 
 
  
  
   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE G: EMAIL FROM NHLS IT CONFIRMING THE CHANGE IN THE 
PROJECT PLAN FOR THE ROLLOUT OF THE TRAKCARE LIMS IN THE 
EKURHULENI HEALTH DISTRICT 
 
  
 
 
  
  
   
 
 
 
 
 
 
ANNEXURE H: EMAIL COMMUNICATION WITH LABORATORY MANAGERS 
 
 
  
  
 
 
 
 
 
 
 
ANNEXURE I: PRINTERS TAX INVOICE 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE J: STUDY DATA PRESENTATION AS WELL AS DELIVERY OF 
PRE-ART REGISTER AND QUESTIONNAIRE 
 
Letters to the study sites to propose dates and time for the study results 
presentation and delivery of pre-ART register and questionnaire
 
Attendance register at the Far East Rand study site 
 
  
Attendance register at the Tembisa Hospital study site briefing for the senior 
management team 
 
 
  
Screenshot of the pre-ART Register for the Tambo Memorial study site 
 
 
  
Completed Pre-ART Questionnaire from the Far East Rand study site 
 
 
  
 
 
 
 
 
  
 Conceptual Framework 
  
 
 
 
 
 
 
 
ANNEXURE K: CONCEPTUAL FRAMEWORK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conceptual Framework 
 
 
  
 
 
 
 
 
 
 
ANNEXURE L: PROPOSED PRISM MODEL FOR IMPLEMENTATION 
 
 
 
 
 
 
 
 
 
 
 
Proposed PRISM Model for implementation 
 
 
 
  
 
 
 
 
 
 
 
ANNEXURE M: ETHICAL CONSIDERATIONS RELATED TO DATA COLLECTION 
 
 
 
 
 
 
 
 
 
 
 
 
Ethical considerations related to data collection 
 
 
Relationship to the 
practice of science 
(Mouton 2011:239). 
Objectivity and integrity: The researcher must at all times maintain integrity and 
objectivity in the conduct of the study. This included adhering to the highest technical 
standards during the study, indicating the limitations of the study findings and 
undertaking to present the results of the study impartially.  
Fabrication of data: The researcher will under no circumstances change the data or 
observations for the study. 
Relationship to 
society(Mouton 
2011:241) 
 
No secret of clandestine research: The researcher has obtained consent to conduct the 
study from the Gauteng Department of Health. Additionally the approval to conduct the 
study was obtained from the chief operating officers (CEO’s) of the three study sites. 
Consent to conduct the study was request from the NHLS business manager (BM).  
Obligation to the free and open dissemination of research results: The study results have 
been shared with the relevant national, provincial, district Department of Health. 
Responsibility to funders and sponsors of research: The study results have been shared 
within the National Priority Programmes (NPP) CD4 Unit at the NHLS who are the 
sponsors of this research. 
Relationship to the 
subjects of science 
(Mouton 2011:243). 
Right to privacy: The patient’s right to privacy has been ensured both when CD4 samples 
were being collected as well as the provision of data from the CDW that excluded any 
patient identifiers. 
 Right to anonymity and confidentiality: The NHLS Corporate Data Warehouse (CDW) 
has extracted the CD4 and CCMT programme status data without any patient identifiers. 
The study therefore received anonymous laboratory data and did not require informed 
consent 
The right to full disclosure: All aspects of the study were disclosed to the Gauteng CCMT 
programme manager, the CEO’s at the study sites and finally the study site managers. 
The right not to be harmed in any manner: This study had no experimental or 
interventional aspects. As the study related to the collection of information during routine 
healthcare service delivery the patient’s were not harmed in any manner 
The rights of vulnerable subjects: The study collected additional information about the 
patient programme status (pre-ART or ART) offered during routine healthcare delivery; 
hence the rights of all subjects (including vulnerable subjects) were not compromised. 
 
 
 
 
